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ABSTRACT
In oviparous vertebrates, estrogen stimulates the liver to produce vitellogenin.
Vitellogenin induction is a useful biomarker for exposure to endocrine disruptors,
specifically environmental estrogens. The objective of this project was to design in vivo
bioassays for environmental estrogens based on induction of vitellogenin in male
Xenopus laevis.  Frogs were exposed to ethinyl-estradiol by injection or immersion for
different times and doses, than vitellogenin induction was assessed. An ELISA was
developed to measure serum vitellogenin.  Additionally, a vitellogenin rt-PCR assay was
developed using species-specific vitellogenin primers, to detect mRNA induction.  It was
established that the induction of serum vitellogenin and hepatic vitellogenin mRNA were
time and dose responsive to ethinyl-estradiol.  Frogs were also immersed in xenobiotic
estrogens.  Serum vitellogenin was not induced by the xenobiotics; however, hepatic
vitellogenin mRNA was, confirming the sensitivity of this technique.  These data reveal
the usefulness of vitellogenin induction assays for detecting exposure to estrogenic
compounds.
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1Introduction
The Endocrine System
The endocrine system works hand-in-hand with the nervous system to maintain
the body’s internal steady state; react to stimuli; regulate growth, development, and
reproduction; and produce, use, and store energy (Atlers, 2000; Eubanks, 1997).  It
comprises a group of specialized organs and glands that produce and secrete over fifty
different hormones into the bloodstream (Alters, 2000, Eubanks, 1997).
As the body’s chemical messengers, hormones transfer information and
instructions from one set of cells to another (Eubanks, 1997; O’Malley and Strott, 1991).
Hormones only recognize specific cells, the target cells, which have a specific receptor
molecule embedded within their cell membranes or located within their cytoplasm
(Atlers, 2000; Eubanks, 1997).  When a hormone binds to its specific receptor a chain of
events in the target cell is activated, resulting in an effect (Alters, 2000).
There are two general types of hormones, peptide hormones and steroid
hormones.  Peptide hormones are hydrophilic (and mostly large) and bind to receptors on
the surface of target cells.  These receptors are transmembrane proteins and binding of
the hormone to its specific receptor initiates a cascade of intracellular signals that may
alter the behavior of the cell (such as opening or closing membrane channels) or stimulate
or repress gene expression in the nucleus by turning on or off the promoters and
enhancers of genes (Carlstedt-Duke et al., 1995).
2Steroid Hormones
Steroid hormones are the other class of hormones that are made from cholesterol
(Beato, 1989; O’Malley and Strott, 1991).  Steroid hormones are lipid soluble and pass
freely through the lipid bilayer of the cell membrane.  The classic steroidal hormones are
estrogens, progestins, androgens, glucocorticoids, mineralocorticoids, and vitamin D
derivatives, which are all structurally related by a common
cyclopentanoperhydrophenanthrene nucleus (Carlstedt-Duke et al., 1981; O’Malley and
Strott, 1991; Selcer and Leavitt, 1991). The properties that differentiate the subgroups of
steroid hormones are due to the specific functional groups attached to the four fused rings
(Selcer and Leavitt, 1991).
Estrogens are involved in regulating female reproduction, androgens are involved
in regulating male reproduction, progestins aid in pregnancy, glucocorticoids regulate
aspects of metabolism and stress responses, mineralocorticoids assist in salt metabolism,
and vitamin D and its derivatives are important in bone metabolism (O’Malley and Strott,
1991).
Steroid hormones are secreted by a variety of glands into the bloodstream, where
they circulate bound mostly to plasma transport proteins.  These hormones, being
lipophilic, can diffuse across the plasma membrane and into the cells.  In the target cells,
steroid hormones combine with their specific receptors and form a hormone/receptor
complex that alters cell function (Beato, 1989; Korach, 1994; O;Malley and Strott, 1991).
Receptors for most steroid hormones are present in limited cell types; for
example, receptors fro estrogens are present mostly in female reproductive tissues, and
3receptors for androgens are present mostly in male reproductive tissues (O’Malley and
Strott, 1991).
All steroid hormones operate through a similar mechanism.  Steroid hormones
regulate specific functions by binding to and activating receptors, which are gene-
regulatory molecules.  The receptors bind steroid hormones tightly and are very specific;
they are also present in low concentrations in cells.  After binding of the hormones to
their specific receptors, the receptors undergo a conformational change, which alters the
receptor from an inactive to an active state.  Prior to binding, the receptors are associated
with chaperone proteins, more specifically heat shock proteins.  Binding causes the
dissociation of the chaperone proteins and allows the hormone/receptor complex to
interact with the DNA at specific sites within hormone-dependent genes (Carlstedt-Duke
et al., 1995).  Binding of the hormone/receptor complex to the regulatory elements of
genes either activates or suppresses their transcription.
The steroid hormone receptor is comprised of three distinct functional domains.
The first is the amino-terminal domain, which regulates transcriptional activity.  The
second is the DNA-binding domain, which is responsible for dimerization, DNA-binding,
and some transcriptional functions.  The third is the carboxy-terminal domain, which
contains the hormone-binding site and interacts with the chaperone proteins (Carlstedt-
Duke et al., 1995).  The receptors hormone-binding domain recognizes the three-
dimensional configuration of a particular hormone with high affinity.  In the absence of
hormones, the receptor protein binds to heat shock proteins (usually hsp90).  The role of
the heat shock protein is to maintain the correct folding of the receptor and to mask the
DNA-binding site of the receptor protein, blocking genome interactions in the absence of
4the appropriate hormone (Carlstedt-Duke et al., 1995).  In addition to assisting in folding,
heat shock proteins also protect the receptors from degradation by cellular proteases
(O’Malley and Strott, 1991).  After the hormone binds to the receptor, the
hormone/receptor complex binds to the DNA as a dimer.  Dimers bind more tightly and
with greater stability than monomers; therefore, they have a greater effect on gene
expression (O’Malley and Strott, 1991).
    Once the receptor has become activated, it alters cell function by binding to the
DNA at specific sites called hormone-response elements (HREs), which are specific
sequences of DNA located near hormone-dependent genes (Carlstedt-Duke et al., 1995).
The HREs are characterized by short inverted repeats separated by a fixed number of
nucleotides, which varies depending on the steroid receptor types (Carlstedt-Duke et al.,
1995; O’Malley and Strott, 1991).  Binding of the hormone/receptor complex to HREs
causes a disruption of the chromatin structure, supplying a naked region of the DNA.  By
disrupting chromatin structure, access to transcription factors is achieved (Carlstedt-Duke
et al., 1995; O’Malley and Strott, 1991).  The receptor attracts transcription factors and
RNA polymerase to transactivation domains on the receptor, initiating transcription.  The
production of mRNA via gene transcription requires the binding of transcription factors
and RNA polymerase to the gene promoter to form a complex (Carlstedt-Duke et al.,
1995; O’Malley and Strott, 1991).
Estrogen
Estrogens, as a subclass of steroid hormones, are made primarily in the ovaries of
humans and other animals.  17b-estradiol is the most abundant and potent estrogenic
hormone, followed by estrone and estriol (Carlstedt-Duke et al., 1981; Eubanks, 1997;
5Selcer and Leavitt, 1991).  Estrogen action starts when it enters the cell by passive
diffusion and binds to an estrogen receptor in the nucleus.  Binding forces the heat shock
proteins to dissociate and the receptor is then able to bind to the hormone response
elements.  The hormone/receptor complex then stimulates gene transcription and the
formation of mRNA.  The mRNA’s are then translated into proteins for a cellular
response to the estrogenic hormone (Selcer and Leavitt, 1991).
Estrogens play a role in secondary sex characteristics, such as the female pattern
of body fat and development of mammary glands.  Estrogens also influence sexual
behavior (Eubanks, 1997; Johnson and Everitt, 1995) and are involved in sexual
differentiation of the brain and gonads (Ho, 1987).  However, in nonmammalian
oviparous adult female vertebrates, the most important action of estrogen is its regulation
of the egg yolk precursor protein vitellogenin (Ho et al., 1981, 1982; Ho, 1987; Selcer
and Leavitt, 1991; Tata and Smith, 1979).
Vitellogenin and Vitellogenesis
A characteristic feature of oviparous vertebrates is the accumulation in the oocyte
of a nutritive material used during embryonic development (Ho, 1987; Redshaw, 1972;
Skipper and Hamilton, 1977; Wahli et al, 1981).  This stored material is referred to as
yolk and is derived from the protein vitellogenin.  The formation of yolk is a complex
process, involving not only the oocyte, but also the liver (Follett and Redshaw, 1972; Ho,
1987; Redshaw, 1972; Skipper and Hamilton, 1977; Wallace and Bergink, 1974).
Vitellogenesis is vital for all oviparous species.  Gonadotropins control ovarian
growth by regulating both estrogen production and yolk uptake (Follett and Redshaw,
1972; Ho et al., 1981, 1982; Ho, 1987; Redshaw, 1972).  When the hypothalamus
6receives the cues that the mating season has arrived, it secretes gonadotropin-releasing
hormone, which is received by the pituitary.  The pituitary responds by secreting
gonadotropic hormones into the blood.  This stimulates the follicle cells to secrete
estrogen, which instructs the liver to synthesize and secrete vitellogenin.  Vitellogenin is
then taken up by the oocyte where it is broken down into the yolk proteins lipovitellin
and phosvitin (Skipper and Hamilton, 1977; Redshaw, 1972; Follett and Redshaw, 1972;
Ho et al., 1981, 1982; Ho, 1987; Selcer et al., 2001).  Estrogen induces vitellogenin
expression at both the transcriptional and translational levels (Brock and Shapiro, 1983;
Wallace and Bergink, 1974).
Studies of amphibian vitellogenesis have focused on Xenopus laevis.  Xenopus
vitellogenin is characterized as a phospholipoglycoprotein with a molecular weight of
400-500 kDa (Ho, 1987).  This form is a dimer molecule made of two polypeptides, each
with a weight of 200 kDa (Wahli et al., 1981).  The vitellogenin polypeptide has both
lipid-rich and phosphate-rich regions, separated by enzymatic cleavage in the oocyte into
lipovitellin and phosvitin.  Vitellogenin is glycosylated, containing 1.4% carbohydrate.
The lipovitellin region contains 20% lipid and the phosvitin region has a large number of
serine residues, which are mostly phosphorylated, resulting in 10% phosphorus (Palmer
and Selcer, 1996; Wahli et al., 1981).  Xenopus vitellogenin is resistant to proteolytic
activity, making it relatively easy to isolate (Ho, 1987).  Vitellogenin is encoded by four
genes, A1, A2, B1, and B2, which are all under estrogen control (Wahli et al., 1981).
Estradiol acts in mature female Xenopus laevis to stimulate production of
vitellogenin.  Vitellogenin is normally absent from the blood of males, but when
7estrogens are given to males serum vitellogenin is induced.  The response to estrogen is
specific and also dose-and time-dependent (Redshaw et al., 1969).
Endocrine Disruption
Endocrine disruption occurs when external agents interfere with the normal
function of hormones, such as estrogen (Solomon and Schettler, 2000).  Under normal
conditions the body’s hormones are delicately balanced and altering this balance can
wreak havoc on the numerous systems regulated by the endocrine system (Gilbert, 2000).
Endocrine disruptors alter hormonal functions by (Solomon and Schettler, 2000; Soto et
al., 1995):
• mimicking or partly mimicking hormones;
• blocking, preventing, or altering hormonal binding to hormone
receptors;
• altering production and breakdown of natural hormones; or
• modifying the production and function of hormone receptors
Endocrine disrupting chemicals are made commercially for specific purposes or
are released as by-products of manufacturing processes.  Since the turn of the century, a
wide variety of suspected endocrine disrupting chemicals have been released into the
environment (Colborn et. al., 1993; Safe, 1995).  Such chemicals include pesticides,
herbicides, insecticides, pharmaceuticals, ingredients in ordinary household products, and
industrial chemicals (Safe, 1995).
Environmental Estrogens
Many of the aforementioned environmental endocrine disruptors interfere with
the normal biological activities of the sex steroid hormone estrogen.  These chemicals are
8termed environmental estrogens, and are the most studied of all the endocrine disruptors
(McLachlan, 1993; McLachlan and Arnold, 1996; Stancel et al., 1995; Turner and
Sharpe, 1997).  These include synthetic estrogens, which are designed to be estrogenic,
naturally occurring phytoestrogens, and a variety of chemicals, which are accidentally
estrogenic (Colborn et al., 1993; McLachlan, 1993; Turner and Sharpe, 1997).
Environmental estrogens do not need to structurally resemble estrogen in order to mimic
its effects.  They act by interfering with steps in the chemical-signaling pathway through
which estrogens normally work (McLachlan and Arnold, 1996).
Environmental estrogens include: (Eubanks, 1997; Soto et al., 1995; Turner and
Sharpe, 1997)
• Pesticides
o Insecticides- dichlorodiphenyltrichloroethane (DDT),
endosulfan, dieldrin, methoxychlor, kepone, toxaphene,
chlordane
o Herbicides- atrazine, alachlor, nitrofen
o Fungicides- benomyl, mancozeb, tributylin
• Products associated with plastics- bisphenol-A, phthalates
• Pharmaceuticals- birth control pills, diethylstilbesterol (DES),
cimetidine
• Ordinary household products- breakdown products of detergents and
surfactants such as, nonylphenol and octyophenol
• Industrial chemicals- polychlorinated biphenyls (PCBs), dioxin,
benzopyrene
9• Heavy metals- lead, mercury, cadmium
Estrogenic compounds can interact with estrogen, estrogen receptors, or other
hormones and transcription factors along the pathway of hormone activity (Eubanks,
1997; Stancel et al., 1995). However, natural hormones are more potent than any of the
known synthetic environmental estrogens (except drugs such as DES and birth control
pills).  
Natural hormones are short-lived, do not accumulate in tissue, and are easily
broken down.  Most natural estrogens stay in the bloodstream only minutes or at most a
few hours.  The same holds true for phytoestrogens.  When eaten, these plant compounds
are either flushed out intact or after being broken down are absorbed into the body where
they can act like estrogens (Soto et al., 1995). The estrogenic drugs, on the other hand,
such as ethinyl-estradiol found in birth control pills, are more stable and remain in the
body longer than natural estrogens; however, they are not nearly as persistent as
pesticides and other environmental estrogens.  Synthetic environmental estrogens (Soto et
al., 1995):
• are not easily or readily broken down;
• are long-lived, remaining intact in the environment and in living organisms for
many years; and
• can accumulate in the environment and within the fat and tissue of animals
and humans.
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Wildlife and Human Effects
The evidence for harmful effects of endocrine disruptors is supported by wildlife
studies, laboratory experiments, mechanistic investigations at the molecular and cellular
level, and reports on contamination levels in humans (Colborn, 1995; Danzo, 1998).
Wildlife studies have been a major part of the case against the use of endocrine
disrupting chemicals.  The most significant effects that estrogenic endocrine disruptors
have on wildlife populations are:  abnormal mating and parenting, inability to breed,
thyroid system disorders, interrupted sexual development, and reduced immune response
(Carey and Bryant, 1995; Colborn et al., 1993; Hayes et al., 2002a,b, Toppari et al., 1996;
Turner and Sharpe, 1997). Specific studies have shown affects on a variety of animals.
For instance, alligators in Florida’s Lake Apopka have suffered from reduced
fertility, reduced penis size, and shifts in sex ratios with predominantly females being
born due to a chemical spill (Guillette et al., 1996).  Additionally, loss of Great Lakes
fish, especially the lake trout in the 1950’s was linked to dioxin contamination.  The
contamination of the Albatross and minke whale in the North Pacific was associated with
PCB, furan, and dioxin exposures (Krimsky, 2001). Some other populations studied
include: sea gulls, bald eagles, panthers, harbor seals, turtles, and other types of reptiles
and birds (Kavlock, 1997; Raloff, 1994; Shimasaki et al., 2003; Toppari et al., 1996).
Humans are also becoming a focus of concern regarding the potential negative
impact of endocrine disruptors.  It has been suggested that endocrine disruptors induce
breast cancer, testicular cancer, infertility, and reproductive abnormalities (Raloff, 1993;
Safe, 1995).  It is known that one compound, diethylstilbesterol (DES), causes major
problems in humans.
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The drug DES, a synthetic estrogen, was prescribed to many women in an effort
to prevent miscarriages in the 1950’s and 1960’s (Colborn et al., 1993; Eubanks, 1997;
Krimsky, 2001; McLachlan and Arnold, 1996; Newbold, 1995). In 1971 physicians
reported that numerous teenage girls were developing a very unusual cancer of the vagina
called clear-cell adenocarcinoma (Newbold, 1995).  These girls were daughters of
mothers who took DES.  These daughters also suffered reproductive organ dysfunction,
abnormal pregnancies, a reduction in fertility, immune system disorders, and immune
depression (Colborn et al, 1993).
There is also evidence that DES-exposed sons may have testicular abnormalities,
such as undescended testicles or abnormally small testicles, testicular cancer, sperm
abnormalities, and prostrate disease (McLachlan and Arnold, 1996; Newbold, 1995;
Palmer et al., 2001).  After these findings were reported, John McLachlan (director of the
Tulane/Xavier Center for Bioenvironmental Research in New Orleans, Louisiana)
replicated similar reproductive effects of DES in mouse models, thus showing how
animal studies could provide relevant information for the effects of hormone disruptors in
humans.
The most notorious xenobiotic estrogens are the organochlorine pesticides, which
include DDT, the first recognized endocrine disruptor (Mbongwe et al., 2003; McLachlan
and Arnold, 1996; McLachlan, 2001; Soto et.al., 1994; Thomas and Colborn, 1992).
DDT was thought to be an ideal malaria control agent; however, it soon began to
bioaccumulate at the top of the food chain (Danzo, 1998; Mbongwe et al., 2003;
Norstrom et al., 1988).  DDT was banned in the United States in 1972 after it was found
to induce poor survivorship, reduced reproductive success, reduced sperm counts, and
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eggshell thinning in a variety of birds (Bitman and Cecil, 1970; Gilbertson et al., 2003;
Lukachko, 1999; McLachlan and Arnold, 1996).  In addition, DDT is a known
feminizing agent and has been shown to increase uterine weight in rats, prolong estrous
cycles, and decrease ova implantation in mice (Bitman and Cecil, 1970).
Mechanistically, DDT binds to the cellular estrogen receptor, initiating the same
cascade of events as the natural estrogen hormone.  DDT induces eggshell thinning by
inhibiting the enzyme Ca-ATPase, a calcium transporter from the blood to the oviduct.
Also, the products of DDT breakdown may act as estrogens or compounds that block
androgens (Fairbrother et al., 1999).
In 1940, Charles Broley began studying and banding Florida bald eagles.
Suddenly the number of eaglets began dropping and Broley witnessed strange behavior in
many of the pairs.  At nesting sites the adult birds seemed to be indifferent to nesting,
courtship, and mating.  Broley concluded that 80 percent of Florida’s bald eagles were
sterile, a direct result of DDT exposure (Colborn et al., 1996).
 Early in the 1960’s scientists noticed that bird populations were also declining in
Europe.  Eventually this decrease was linked to the use of DDT (McLachlan and Arnold,
1996).  Important works by D. Michael Frye showed that sea-gull eggs exposed to DDT
developed as females, no matter what their genetic sex (Frye and Toone, 1981;
McLachlan and Arnold, 1996).  In addition to that finding, Schreiber spotted some gull
nests with a large number of eggs.  Gulls usually do not incubate more than three eggs at
a time, therefore, Schreiber suspected that more than one female was laying in these
nests.  In 1972, George and Molly Hunt noticed the same situation on Santa Barbara
Island.  They observed thinning eggshells in the gull colony, causing them to believe the
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birds were suffering from DDT exposure.  Over the next two decades nesting female
pairs would be found among the herring gulls in the Great Lakes, glaucous gulls in Puget
Sound, and roseate terns off the coast of Massachusetts (Colborn, et al., 1996).   Finally,
DDT exposure has also been implicated in reduced penis size of alligators from Lake
Apopka, following a pesticide spill (Guillette et al., 1996).  These observations that DDT
could behave like estrogen provided a construct for understanding that environmental
chemicals may possess hormonal activity (Gray et al., 1989; McLachlan and Arnold,
1996).
Polychlorinated biphenyls (PCBs) are another class of widely distributed
endocrine disruptors (Bitman and Cecil, 1970; Jonathan and Steinmetz, 1998;
McLachlan, 2001).  PCBs were used from 1930 until the late 1970s as insulating
materials in electrical capacitors and transformers, plasticizers in wax, in paper
manufacturing, and in industrial applications (Gilbert, 1994).  Anniston, Alabama is
infamous for PCB contamination, where PCBs can still be found in the air, water, soil,
wildlife, and in the residents themselves (Kroft, 2002).  This exposure led to deformed
fish, liver damage in exposed rats, and possible cancer, heart disease, and diabetes in the
townspeople (Kroft, 2002).  In addition to people, PCB’s bioaccumulate in fish-eating
birds, feminizing male sex organs of exposed seagulls and causing a life-threatening bill
deformity in the cormorant (Fairbrother et al., 1999; Gould et al., 1997; McLachlan and
Arnold, 1996; Raloff, 1994).  PCB’s induce reproductive defects, uterotropic effects, and
estrous cycles, all of which impair fertility.  They have been shown to become even more
estrogenic as they are metabolized by the body (Blais et al., 2003; de Solla et al., 2002;
Selcer et al., 2001).  When PCB’s bind to the estrogen receptor they interfere with or
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initiate the same sequence of events as natural estrogen (Fairbrother et al., 1999; Korach,
1994).
Bergeron et al. (1994) showed the developmental consequences of exposing
turtles to estrogenic chemicals.  Normally sexual differentiation in turtles is dependent on
the temperature at which the eggs develop; however, eggs incubated at the male-
producing temperature developed as females when they were exposed to either natural
estrogens or estrogenic PCB’s.
DDT and PCB’s are no longer in use in the U.S; however, other chemicals are
gaining recognition as important endocrine disruptors. One group is alkylphenols and
alkyphenol polyethoxylates (APEO’s), which both have estrogenic activity and are used
in pesticides, detergents, paints, and cosmetics (Danzo, 1998; Nimrod and Benson, 1996;
Soto et al., 1991).  Nonylphenol and octylphenol, the products of APEO degradation by
microorganisms, are very stable in the environment and cause estrogenic responses in a
number of organisms, including male reproductive defects (Danzo, 1998; Mosconi et al.,
2002; Soto et al., 1991).  Bisphenol-A, a commonly used plasticizer, is also found in the
aquatic environment and known to be estrogenic in vertebrates and invertebrates (Bitman
and Cecil, 1970; Danzo, 1998; Harris et al., 1997; Jonathan and Steinmetz, 1998;
McLachlan, 2001; Soto et al., 1995; Turner and Sharpe, 1997).  Atrazine, the most
commonly used herbicide in the United States and the world, has recently surfaced as
another endocrine disruptor.  Atrazine affects sexual differentiation by inducing
aromatase, which converts androgens into estrogens (Hayes et al., 2002a).  Breeding
amphibians are exposed to very high concentrations of atrazine from agricultural runoff
(Bringolf et al., 2004; Hayes et al., 2002a,b).
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The most recently considered sources of endocrine disruptors include: runoff from
sewage treatment plants, pulp/paper mills, and other manufacturing factories (Kirby et
al., 2004; Lukachko, 1999).  Male flounder, collected from estuaries in the United
Kingdom, show biological responses that are indicative of estrogen exposure, such as
elevated levels of plasma vitellogenin in males (Kirby et al., 2004).  These estuaries
receive high quantities of domestic sewage, which is known to cause estrogenic effects in
exposed fish (Sumpter, 1995).  The estrogenic activity of sewage effluents may be due to
the presence of natural and synthetic estrogens, such as 17ß-estradiol, estrone, and
ethinylestradiol (Seki et al., 2003).  For example, the increase in the number of women
using birth control pills has placed an increased amount of estrogen and its breakdown
products through sewage treatment plants and into the waterways (Kirby et al., 2004;
McLachlan, 2001).  Alkylphenols, such as octylphenol and nonylphenol, have also been
implicated as sources in sewage effluent, due to their presence in nonionic surfactants
used in the manufacturing of cleaning agents, plastics, paper, cosmetics, and food
products (Karels et al., 2003; Seki et al., 2003). This impacts wildlife because these
waters are the breeding ponds for mature animals and nurseries for offspring (Kirby et al.,
2004; Lukachko, 1999; McLachlan, 2001).
Need for Biomarkers
The relationship between environmental contaminants and wildlife and human
effects is not fully understood.  Therefore, there is a need for assays that can detect
endocrine disruptors and assess their effects.  In fact, Congress passed the Safe Drinking
Water Act and the Food Quality Protection Act, mandating EPA to develop tests to
characterize and detect the endocrine activity of pesticides, commercial chemicals, and
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environmental contaminants.  These acts stated that EPA was to develop an endocrine
disruptor-screening program, and screen for disruptors in drinking water sources.  The
committee, called EDSTAC (Endocrine Disruption Screening and Testing Advisory
Committee), designed and implemented a program that focuses on providing methods
and procedures to detect and characterize the endocrine activity of environmental
contaminants (EDTAC, 1998).  The goal of this program is to provide scientific data on
87,000 chemicals and identify ones that are endocrine disruptors.  Currently, EPA is in
the process of initial screening (Tier 1 screening) and testing (Tier 2 testing) (EDSTAC,
1998).
Declining Amphibians
As evidenced above, endocrine disruptors have been associated with many health
and reproductive problems in wildlife and laboratory animals.  It is possible that they also
are impacting amphibian populations.
One hot summer day in 1995 eight middle school children
planning a simple study of wetland ecology began collecting
leopard frogs from a small pond near Henderson, Minn.  To their
astonishment, one captured after another had five or more hind
legs, some twisted in macabre contortions.  Of the 22 animals they
caught that day, half were severely deformed.  A follow-up search
by pollution-control officials added to the gruesome inventory.
Occasional frogs in the pond had no hind limbs at all or had mere
nubbins where legs should be; others had one or two legs sprouting
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from the stomach.  A few lacked an eye (Blaustein and Johnson,
2003).
This story gained national media attention and raised many questions.  Researchers soon
began investigating this phenomenon and it became clear that this was not an isolated
incident, it was occurring all over the U.S. and even the world.
In the United States today at least 20 species of frogs are in distress in all parts of
their natural range, which makes up 10% of U.S. amphibians (Phillips, 1999; Wyman,
1990).  Many amphibian populations are declining and extinction has even occurred in a
few populations. Endocrine disruptors are considered to be potential culprits of this
decline.  These chemicals have the potential to interfere with amphibian growth and
development (Carey and Bryant, 1993).
The decline in amphibian populations requires attention not only because we need
to know why they are dying, but also we need to know what their death will mean for the
future (Mattoon, 2000).  Since many amphibians play crucial roles in many ecosystems,
an important aspect of amphibian decline is lost potential.  Amphibians are very diverse
and very little is known about them (Mattoon, 2000).
It has been some time since global amphibian decline gained attention and there is
no doubt that the problem is real (Mattoon, 2000; Wyman, 1990).  However, we are still
unsure of the causes behind this tragedy.  Scientists are working to determine the possible
causes of decline and are trying to elucidate a mechanism of action.
A recent paper by Hayes et al. (2002a) highlights the effects of atrazine, the most
commonly used herbicide in the United States, on the male frog Xenopus laevis.  Males
exposed to atrazine suffered from hermaphroditism and demasculinized larynxes.  Plasma
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testosterone levels in mature males were also examined (Hayes et al., 2002a).  Atrazine
exposed males suffered a 10-fold decrease in testosterone levels when exposed to 25 ppb
atrazine.  Hayes and his fellow scientists believe that atrazine induces aromatase and
promotes the conversion of testosterone to estrogen.  This explains the demasculinization
of the male larynx and production of hermaphrodites.  This study used realistic exposures
and suggests that other amphibian species exposed to atrazine in the wild could also be at
risk.  Actual effects in the wild were demonstrated for Rana pipiens (Hayes et al., 2002b).
This compound and other environmental endocrine disruptors may be a factor in global
amphibian declines (Hayes et al., 2002a,b), which makes further study a necessity.
Unfortunately, few other studies exist on whether reproduction of amphibian populations
in the wild have been affected by endocrine disruptors (Carey and Bryant, 1995).
Therefore, vulnerability of eggs, larvae, and adults of various amphibian species to
different endocrine disruptors needs to be established by first constructing a good model
from which to set baseline exposure limits.
Model Organism- Xenopus laevis
Due to the need for amphibian data, Xenopus laevis, the African clawed frog was
chosen as the model organism.  The African clawed frog is a member of the family
Pipidae, and is one of 14 species of Xenopus.  Xenopus laevis is native to sub-Saharan
Africa and normally lives in murky water found in stagnant pools (Beck, 1994).
Xenopus laevis has been the subject of substantial laboratory research.  There are
many advantages to using Xenopus laevis as a model organism.  They are fully aquatic,
allowing the evaluation of effects based on concentrations in the aquatic environment.
They are available commercially and require little maintenance (Bogi, 2003).  Finally,
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their vitellogenin gene has been cloned and sequenced, and their response to estrogen
well documented, making them the perfect candidates for research (Tata and Smith,
1979; Wahli et al., 1981).  This study aimed to demonstrate the suitability of the Xenopus
model as a test organism to biomonitor the effects of environmentally relevant xenobiotic
endocrine disruptors using vitellogenin as the biomarker.
20
Specific Aims
1.) To develop assays for detecting induction of serum vitellogenin (enzyme-
linked immunosorbent assay (ELISA)) and hepatic vitellogenin mRNA
(reverse-transcriptase polymerase chain reaction (rt-PCR)).
2.) To characterize changes in serum vitellogenin and hepatic vitellogenin mRNA
associated with exposure to ethinyl-estradiol by injection or immersion for
different times and doses.
3.) To characterize the changes in serum vitellogenin and hepatic vitellogenin
mRNA associated with exposure by immersion to various xenobiotic
estrogens (i.e. endocrine disruptors), including atrazine, nonylphenol,
octylphenol, and bisphenol-A.
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Materials and Methods
Chemicals
Ethinyl-estradiol was purchased from Sigma-Aldrich Corporation (St. Louis,
MO).  Atrazine, nonylphenol, and octylphenol were purchased from Chem Service (West
Chester, PA) and bisphenol-A was purchased from Aldrich Chemical Co. (Milwaukee,
WI).   These chemicals were certified standard grade.
Animals
Adult male Xenopus laevis were obtained from Xenopus I (Ann Arbor, MI) for all
experiments and housed, either two or three per tank, at room temperature in 2.5 gallon
aquaria containing 4 L of aged water, changed twice weekly.  Frogs in Experiments 1-6
were fed Xenopus Frog Brittle (NASCO) once a week; however, Experiment 7 frogs were
not fed.  Frogs were kept on a 12 h:12 h light:dark photoperiod and exposed to
experimental agents by either immersion or injection.  They were sacrificed by
decapitation.  Blood was collected, allowed to clot for 2 h at room temperature, and
centrifuged twice at 2,500 x g for 10 min to make serum, which was then stored at –20oC.
Livers were also removed and frozen immediately in liquid nitrogen, and then stored at
–80oC for future RNA extraction.
Experimental Design
The experimental design was adapted from Palmer et al., (1998), Selcer et al.,
(2001), and Schultz et al., (2003).  Ethinyl-estradiol or xenobiotic estrogens were
administered by intraperitoneal injection (i.p.) or immersion, in order to evaluate both
time course and dose-response effects.  Frogs were injected with ethinyl-estradiol
dissolved in propylene glycol or propylene glycol alone (vehicle controls).  Injection
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schedules are listed in the description of each experiment.  Frogs were also immersed in
ethinyl-estradiol dissolved in methanol or methanol alone (0.1% vehicle controls).
Immersion schedules are listed in the description of each experiment.  Lastly, frogs were
immersed in various xenobiotic estrogens dissolved in methanol or methanol alone (0.1%
vehicle controls).  Immersion schedules are listed in the description of each experiment.
    During the course of each experiment, all animals were housed in the Duquesne
University Animal Care Facility.  All procedures used were approved by the IACUC.
Experiment 1: Generate Positive Controls
Four adult female Xenopus laevis were injected (i.p.) weekly for 3 weeks with
0.25 cc of ethinyl-estradiol (1 mg/ml) in propylene glycol (Table 1).  The ethinyl-
estradiol solution was prepared by dissolving ethinyl-estradiol in acetone (1 mg/0.1ml
solution). This solution was diluted 1:10 in propylene glycol to create a 1 mg/ml ethinyl-
estradiol emulsion.  The emulsion was dried with a nitrogen-gas stream for 30 min and
incubated overnight to allow for acetone evaporation.  The solution was again dried with
a nitrogen-gas stream and incubated overnight.  After 3 weeks the frogs were sacrificed,
and blood and livers were collected.
Table 1.  Experiment 1: Positive Control Injection and Termination schedule
Specimen Injection (0.25 cc ethinyl-estradiol (1
mg/ml)) Dates
Termination
Schedule
Female
343
Once a week- 5/6, 5/12, 5/20 3 Weeks- 5/27
Female
344
Once a week- 5/6, 5/12, 5/20 3 Weeks- 5/27
Female
345
Once a week- 5/6, 5/12, 5/20 3 Weeks- 5/27
*Female
346
Once a week- 5/6, 5/12, 5/20 Died prematurely
(5/22)- Did not use
in study
Average frog weight 135.0 g
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Experiment 2: Time Course Injection
Fifteen adult male Xenopus laevis were injected (i.p.) with 0.20cc of ethinyl-
estradiol (1 mg/ml).  Five males were left untreated to serve as negative controls.   Frogs
were sacrificed on a time-course of 1, 2, or 4 weeks (Table 2) at which times blood and
livers were collected.
Table 2.  Experiment 2: Time Course Injection and Termination Schedule
Specimen
(5 per group)
Injection (0.20 cc ethinyl-
estradiol (1 mg/ml) Dates
Termination
Schedule
Negative Control Males
347-351
No injection 5/22
1 Week Males
352-356
Once-5/22 1 week- 5/28
2 Week Males
357-361
Once-5/22 2 weeks- 6/4
4 Week Males
362-366
Once- 5/22 4 weeks- 6/18
Average frog weight 30.0 g
Experiment 3: Time Course Immersion
Fifteen adult male Xenopus laevis were immersed in ethinyl-estradiol (1 µg/L).
Five males were treated with methanol (0.1%) to serve as vehicle controls and 5 males
were left untreated to serve as negative controls.  Frogs were sacrificed on a time course
of 1, 2, or 4 weeks at which times blood and livers were collected.
Ethinyl-estradiol for immersion was prepared as follows: first, a stock solution of
ethinyl-estradiol (1 mg/ml) in methanol was made (Shultz et al., 2003).  The stock
solution was then diluted 1:1000, to achieve a concentration of 1 µg/ml.  To arrive at a
final concentration in each tank of 1 µg/L, 1 ml of the 1 µg/ml solution was added per 1 L
of water in each tank.  This also kept the methanol concentration in each tank at 0.1%,
which was suggested by Shultz et al., 2003.  The solutions were changed twice a week.
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Table 3.  Experiment 3: Time Course Immersion and Termination Schedule
Specimen
(5 per group)
Immersion (ethinyl-estradiol (1 µg/L) or
*methanol (0.1%)) Start Dates
Termination
Schedule
Negative Control
Males
367-371
___________ 7/9
Vehicle Control
Males
372-376
*7/10- water changed twice weekly 3 Weeks- 7/30
1 Week Males
377-381
7/10- water changed twice weekly 1 Week- 7/16
2 Week Males
382-386
7/10- water changed twice weekly 2 Weeks- 7/23
4 Week Males
387-391
7/10-water changed twice weekly 4 Weeks- 8/6
Average frog weight 31.3 g
Experiment 4: Primed Injection
This experiment was intended to ascertain the impact of previous estrogen
exposure on serum vitellogenin and vitellogenin mRNA induction after a 30-day lag
period, followed by estrogen injection at 4-hour intervals (Table 4).  Stock ethinyl-
estradiol (1 mg/ml) prepared for Experiment 1 was used for injections.  The frogs were
divided into 2 treatment groups, primed (12 adult male Xenopus laevis) and unprimed (12
adult male Xenopus laevis).  Primed males were injected (i.p.) one time with 0.20 cc
ethinyl-estradiol (1 mg/ml).  After 2 weeks, 3 frogs were terminated to ensure that serum
vitellogenin and vitellogenin mRNA were detectable.  The remaining 9 frogs were left
without further treatment for 30 days.  After 30 days they were re-injected (i.p.) with
ethinyl-estradiol (1 mg/ml) and terminated on a time course of 4, 8, or 12 hours (3 frogs
each time); (Table 4).  Unprimed males were injected (i.p.) one time with 0.20 cc of
vehicle (propylene glycol).  After 2 weeks, 3 frogs were terminated to ensure that serum
vitellogenin and vitellogenin mRNA were not detectable.  The remaining 9 frogs were
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left without further treatment for 30 days.  After 30 days they were injected (i.p.) with
0.20 cc ethinyl-estradiol (1 mg/ml) and terminated on the same time course as the primed
frogs (Table 4).  Later, another group of 5 frogs was added to this experiment.  They were
injected (i.p.) one time with 0.20 cc ethinyl-estradiol (1 mg/ml) and left without further
treatment for 30 days.  Instead of being injected again after 30 days, they were
terminated.  These frogs were used to indicate whether or not serum vitellogenin and
vitellogenin mRNA had declined after 30 days,
Table 4.  Experiment 4: Primed Injection and Termination Schedule
Specimen
(3 per group)
Injection (0.20 cc ethinyl-estradiol
or *0.20 cc propylene glycol)
Dates
Termination
Schedule
2 Week Primed Males
392-394
7/9 2 Weeks- 7/23
4 Hour Primed Males
395-397
7/9
8/21
30 Days-8/21
8 Hour Primed Males
398-400
7/9
8/21
30 Days- 8/21
12 Hour Primed Males
401-403
7/9
8/21
30 Days- 8/21
2 Week Unprimed Males
404-406
*7/9 (vehicle)
8/21
2 Weeks- 7/23
4 Hour Unprimed Males
407-409
*7/9 (vehicle)
8/21
30 Days- 8/21
8 Hour Unprimed Males
410-412
*7/9 (vehicle)
8/21
30 Days- 8/21
12 Hour Unprimed Males
413-415
*7/9 (vehicle)
8/21
30 Days- 8/21
Primed Males No 2nd
 Injection- 441-445
9/25 30 Days- 10/24
Average frog weight 30.5 g
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Experiment 5: Dose Response Injection
Twenty-five adult male Xenopus laevis were separated into 5 treatment groups
consisting of:  vehicle control males (propylene glycol), high-dose males (1000 µg/kg
ethinyl-estradiol), medium-dose males (10 µg/kg ethinyl-estradiol), low-dose males (0.1
µg/kg ethinyl-estradiol), and very-low-dose males (0.0001 µg/kg ethinyl-estradiol);
(Table 5).  Vehicle control males were injected (i.p.) one time with 0.20 cc propylene
glycol (vehicle) and terminated at 2 weeks (Table 5).  The other groups were injected
(i.p.) one time with 0.20 cc of the appropriate dose of ethinyl-estradiol and terminated at
2 weeks (Table 5).
Based on an average frog weight of 30 g, it was calculated that for previous
injection experiments (2 and 4) frogs were receiving a dose of 6670 µg/kg (1 mg/ml*0.20
ml (cc)/0.03 kg (30 g)=6.67 mg/kg*1000 µg/mg=6,670 µg/kg).  Therefore, the dosage
was greatly reduced for this experiment.  Injection doses were prepared in propylene
glycol by further dilution of the 1 mg/ml ethinyl-estradiol solution, such that 0.20 cc of
injection resulted in the appropriate dose.
Table 5.  Experiment 5:  Dose Response Injection and Termination Schedule
Specimen
(5 per group)
Injection Date and Dose (0.20 cc
ethinyl-estradiol or *0.20 cc propylene
glycol)
Termination
Schedule
Vehicle Control Males
416-420
*9/25 2 Weeks- 10/9
High Dose Males
421-425
9/24
1000 µg/kg
2 Weeks- 10/8
Medium Dose Males
426-430
9/24
10 µg/kg
2 Weeks- 10/8
Low Dose Males
431-435
9/24
0.1 µg/kg
2 Weeks- 10/8
Very Low Dose Males
436-440
9/25
0.001 µg/kg
2 Weeks- 10/9
       Average frog weight 34.1 g
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Experiment 6: Dose Response Immersion
Adult male Xenopus laevis were divided into the following 7 treatment groups:
negative control males (no treatment), vehicle control males (0.1% methanol), very-low-
dose males (0.0001 µg/L ethinyl-estradiol), low-dose males (0.001 µg/L ethinyl-
estradiol), medium-dose males (0.01 µg/L ethinyl-estradiol), high-dose males (0.1 µg/L
ethinyl-estradiol), and very-high-dose males (1.0 µg/L ethinyl-estradiol); (Table 6).
To begin, a solution of ethinyl-estradiol (1 mg/ml) in methanol was made.  This
solution was then serially diluted in methanol to achieve stock solutions. Each tank
received 1 ml of the appropriate stock solution per 1 L of water to achieve the desired
final dose.  Water was changed twice a week.
Negative control males received no treatment and were terminated upon arrival.
The remaining animals were treated as indicated in Table 6 and were terminated at 2
weeks.
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Table 6.  Experiment 6:  Dose Response Immersion and Termination Schedule
Specimen Immersion Start Date and Dose
(ethinyl-estradiol or *methanol
(0.1%))
Termination
Schedule
Negative Control Males (2)
446-447
________ Upon arrival- 10/24
Vehicle Control Males (4)
448-451
*10/29- Water changed twice
weekly
2 Weeks- 11/12
Very Low Dose Males (5)
453-457
10/29- Water changed twice weekly
0.0001 µg/L
2 Weeks- 11/12
Low Dose Males (5)
458-462
10/29- Water changed twice weekly
0.001 µg/L
2 Weeks- 11/12
Medium Dose Males (5)
463-467
10/29- Water changed twice weekly
0.01 µg/L
2 Weeks- 11/12
High Dose Males (5)
468-472
10/29- Water changed twice weekly
0.1 µg/L
2 Weeks- 11/12
Very High Dose Males (5)
473-477
10/29- Water changed twice weekly
1.0 µg/L
2 Weeks- 11/12
   Average frog weight 33.4 g
Experiment 7: Xenobiotic Immersion
Thirty-three adult male Xenopus laevis were divided into the following 6
treatment groups: negative control males (no treatment), vehicle control males (0.1%
methanol), atrazine males (200 µg/L), nonylphenol males (200 µg/L), octylphenol males
(200 µg/L), and bisphenol-A males (200 µg/L); (Table 7).
To achieve a concentration of 200 µg/L in each tank, stock solutions of each
xenobiotic had to be prepared.  The stock solutions of atrazine, octylphenol, and
bisphenol-A were all prepared in methanol to achieve a concentration of 0.2 mg/ml.
Nonylphenol is a liquid, therefore to determine how much of it to add to methanol the
specific gravity (0.95 mg/µl) had to be used in the following equation: 20 mg/0.95
mg/µl=21.05 µl.  Hence, 21.1 µl of nonylphenol was added to 100 ml of methanol to
attain a concentration of 0.2 mg/ml.  One ml of stock solution was added per 1 L of
water.  All animals were terminated after 2 weeks (Table 7).
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Table 7.  Experiment 7:  Xenobiotic Immersion and Termination Schedule
Specimen Immersion (200 µg/L xenobiotic or
*methanol (0.1%)) Start Date
Termination
Schedule
Negative Control Males (8)
482-489
Water changed twice weekly 2 Weeks- 2/11
Vehicle Control Males (5)
490-494
*1/29- Water changed twice
weekly
2 Weeks- 2/11
Atrazine Males (5)
495-499
1/29- Water changed twice weekly 2 Weeks- 2/11
Nonylphenol Males (5)
500-504
1/30- Water changed twice weekly 2 Weeks- 2/12
Octylphenol Males (5)
505-509
1/30- Water changed twice weekly 2 Weeks- 2/12
Bisphenol-A Males (5)
510-514
1/30- Water changed twice weekly 2 Weeks- 2/12
Average frog weight 30.9 g
Gel electrophoresis
Xenopus laevis serum samples and DEAE fractions were electrophoresed under
denaturing conditions in polyacrylamide gels using sodium dodecylsulfate-
polyacrylamide gel electrophoresis (SDS-PAGE).  BioRad (Hercules, CA) 4-15%
gradient Tris-HCl gels were used.  Serum samples were diluted 1:25 with water and then
mixed 1:1 v/v with Laemmli sample buffer (2% SDS, 62.5 mM Tris-HCl, pH 6.8, 0.01%
w/v bromophenol blue, 25% w/v glycerol, combined with 10% v/v 2-mercaptoethanol;
BioRad Laboratories, Hercules, CA).  DEAE fractions were mixed 1:1 v/v with Laemmli
sample buffer.  Samples were denatured for 4 min in a boiling water bath.  High range
SigmaMarker standards were used in all SDS-PAGE gels.  The proteins and their
molecular weights in the marker are as follows:  Myosin, rabbit muscle 205,000 Da;
Beta-Galactosidase, E. coli 116,000 Da; Phosphorylase b, rabbit muscle 97,000 Da;
Fructose-6-phosphate Kinase, rabbit muscle 84,000 Da; Albumin, bovine serum 66,000
Da; Glutamine Dehydrogenase, bovine liver 55,000 Da; Ovalbumin, chicken egg 45,000
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Da; Glyceraldehyde-3-phosphate Dehydrogenase, rabbit muscle 36,000 Da (Sigma
Aldrich, Saint Louis, MO).  Samples were run at constant current (30 mA) at room
temperature in electrophoresis buffer (25 mM Tris, 192 mM glycine, 0.1% SDS, pH 8.3).
Gels were either stained in Coomassie Blue (25% w/v trichloroacetic acid, 10% v/v
methanol, 0.1% w/v Coomassie Blue R-250) and de-stained in 8% acetic acid or were
used for immunoblotting.
Immunoblotting (Western Blot)
Proteins separated by SDS-PAGE were transferred to polyvinylidene difluoride
(PVDF) membranes (BioRad Laboratories) for immunoblotting.  Kaleidoscope Pre-
stained Standards (BioRad Laboratories) were used in all SDS-PAGE gels for
immunoblotting.  The proteins and their molecular weights in the marker are as follows:
Myosin 210,000 Da (Blue); Beta-Galactosidase 135,000 Da (Magenta); Bovine serum
albumin 82,000 Da (Green); Carbonic anhydrase 38,700 Da (Violet); Soybean trypsin
inhibitor 31,900 Da (Orange); Lysozyme 18,100 Da (Red); Aprotinin 7,400 Da (Blue)
(BioRad).  Transfers were performed in a BioRad Trans-Blot apparatus packed in ice.
Blots were run at 70 V for 3 h.  Transfer buffer was 25 mM Tris, 192 mM glycine, 20%
methanol, pH 8.3.  After transfer, the PVDF membranes were incubated (blocked) in
PBS-Blotto (5 g nonfat dry milk in 100 ml PBS) for 1 h at room temperature, with
shaking.  This solution was replaced with PBS-Blotto (5 g nonfat dry milk in 100 ml
PBS) containing the primary antibody, polyclonal #498- rabbit anti-Xenopus laevis
vitellogenin (Selcer et al., 2001) diluted 1:1000, and the blot was incubated overnight at
room temperature, with shaking.  The PVDF membrane was washed (10 min, with
shaking) once with Tris-Tween (50 mM Tris-HCl (ph 7.5), 0.9% NaCl, 0.05% Tween-
31
20), and twice with Tris-saline (50 mM Tris-HCl (pH 7.5), 0.9% NaCl).  The PVDF
membrane was then incubated in PBS-Blotto (5 g nonfat dry milk in 100 ml PBS)
containing the secondary antibody, peroxidase-coupled goat anti-rabbit serum (BioRad
Laboratories), diluted 1:1000, for 2 h at room temperature.  The PVDF membrane was
washed again as above.  Lastly, the blot was developed with peroxidase-substrate
(diaminobenzidine and urea-hydrogen peroxide tablets (Sigma Chemical Co.) until a
color change occurred.  The reaction was stopped by pouring the peroxidase-substrate off
and rinsing the PVDF membrane with 50 nM Tris-HCl, 0.9% NaCl.
Coomassie (Bradford) Protein Assay
Bovine serum albumin (BSA) was used as the protein standard for protein
determination.  The protein concentration was determined by Coomassie assay (Bradford,
1976).  The Coomassie stain was 0.06 % w/v Coomassie Brilliant Blue G-250 (Fisher)
and 3% perchloric acid (PCA) v/v.
A series of protein dilutions were prepared in duplicate in 13 X 100 mm tubes for
the standard curve.  For serum, 1 µl serum and 1999 µl nanopure water was placed in 13
X 100 mm tubes.  For DEAE fractions, 1000 µl fraction and 1000 µl nanopure water was
placed in 13 X 100 mm tubes.  For purified vitellogenin, 100 µl vitellogenin and 1900 µl
nanopure water was placed in 13 X 100 mm tubes.   Two ml of Coomassie stain was
added to each tube so that the final tube volume was 4 ml.  The tubes were vortexed and
allowed to stand for 5 min.  During this time the spectophotometer (Spec20) was blanked
with a tube containing 2 ml of nanopure water and 2 ml of Coomassie stain.  The
absorbances of the sample tubes were read at 620 nm using the spectrophotometer.
Standards were plotted and the relationship between absorbance and concentration was
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determined by linear regression.  Unknown protein concentration was calculated from the
regression equation.
BCA Protein Assay
The Pierce (Rockville, IL) BCA Protein Assay was used according to the
manufacturer’s instructions.  A standard curve of BSA was prepared with water as the
diluent.  Duplicate concentrations (in µg/tube) were 200, 150, 125, 100, 75, 50, 30, 20,
10, and 5.  Duplicate tubes of vitellogenin serum were prepared using 100 µl of serum.
Two ml of BCA working reagent (1:50) was then added to each tube, vortexed, and
incubated in a 37oC waterbath for 30 min.  During this time the spectrophotometer
(Spec20) was blanked with a tube containing 100 µl of water and 2 ml of BCA working
reagent (1:50).  Tubes were allowed to cool to room temperature and absorbances were
read at 562 nm using the spectrophotometer.  Standards were plotted and the relationship
between absorbance and concentration was determined by linear regression.  Unknown
protein concentration was calculated from the regression equation.
Purification of Xenopus laevis serum vitellogenin
Serum from an ethinyl-estradiol treated female was used as a source of
vitellogenin.  Serum was fractionated on a BioRad Econo Chromatography system
(BioRad Laboratories, Melville, NY, USA), previously shown to be effective for
purification of turtle and frog vitellogenin (Selcer and Palmer, 1995; Palmer et al., 1998),
using a Macro-Prep® DEAE-Support column (1.0 X 15 cm) (BioRad Laboratories,
Hercules, CA).  The equilibration buffer (Buffer A) was 25 mM Tris-HCl, 1 mM
monothioglycerol, pH 7.5 and the gradient buffer (Buffer B) was 500 mM NaCl in
equilibration buffer.  Five-hundred µl of ethinyl-estradiol treated female serum was
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loaded onto the column.  The column was washed with 30 ml equilibration buffer to
remove proteins that do not adhere to the DEAE matrix.  A linear gradient from 0 to 500
mM NaCl was run through the column, totaling 90 ml.  Protein was monitored by
ultraviolet absorbance at 280 nm throughout the chromatography run and 3 ml fractions
were collected.  Protein levels in each fraction were determined separately for each
fraction using a Coomassie protein assay.  Fractions found to contain significant amounts
of protein were evaluated by SDS-PAGE.  The DEAE fractions that contained
vitellogenin (approximately 200 kDa protein) were pooled and dialyzed against DEAE
equilibration buffer using Spectro/Por 1 dialysis membrane (Spectrum, Houston, TX).
After dialyzing overnight the fractions were run through the DEAE column once again
using the same conditions as for serum.  The resulting vitellogenin-containing fractions
were pooled, dialyzed against water, and lyophilized.  The vitellogenin was then frozen at
–20oC.  The concentration of the purified Xenopus laevis vitellogenin was determined by
both Coomassie protein assay and BCA protein assay, as described above.
Purification of Polyclonal Antibody #498- Protein A chromatography
Polyclonal antibody #498 (Selcer et al., 2001) was thawed and sodium azide was
added to a final concentration of 0.05%.  The antibody (10 ml) was clarified by
centrifugation at 15,000 x g for 5 min at 4oC.  The remaining clarified antibody was
passed through the column twice at the rate of 2 ml per min.  The wash was saved.  The
column was then washed with TBS (50 mM Tris-HCl, pH 7.4; 150 mM NaCl; 0.05%
sodium azide) with 10-fold of the volume (100 ml) of antibody that was loaded onto the
column.  Centrifuge tubes (1.5 ml) for collection of eluted sample were filled with 100 µl
of neutralization buffer (NB) (1 M Tris-HCl, pH 8.0; 1.5 M NaCl; 1 MM EDTA; 0.5%
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sodium azide).  The antibody was eluted (1 ml in each centrifuge tube) first using 15 ml
of elution buffer (50 mM Glycine-HCl, pH 2.7) and later using 10 ml of elution buffer
(50 mM Glycine-HCl, pH 1.9) at room temperature.  Coomassie protein assay was
carried out and the appropriate fractions were pooled.  The purified antibody was stored
at 2-8oC.  
Indirect Enzyme-linked immunosorbent assay (ELISA)
Serum samples were diluted (1:9000) with phosphate-buffered saline (PBS) (136
mM NaCl, 1.5 mM KH2PO4, 8.2 mM Na2HPO4, 2.7 mM KCl, pH 7.2), and 100 µl was
added to the individual wells of an Immunosorb microtiter plate (Nunc, Denmark).  PBS
alone was added to wells designated as blanks.  Antigen was allowed to bind to the plate
overnight at 4oC in a covered glass dish with water to create a humidity chamber.  The
plate was then washed 5 times with PBS.  Next, 100 µl of PBS-blotto (5 g nonfat dry
milk in 100 ml PBS) was used to block each well for 1 hr at room temperature, covered,
with shaking.  The plate was washed 5 times with PBS and the PBS-blotto was replaced
with 100 µl of PBS-blotto containing primary antibody (polyclonal #498- rabbit anti-X.
laevis vitellogenin), diluted 1:1000 and the plate was incubated 2 hr at room temperature,
covered, with shaking.  The plate was then washed 5 times with PBS and incubated
covered 2 hr on the shaker at room temperature, with the secondary antibody (goat anti-
rabbit immunoglobulin conjugated to horseradish peroxidase (BioRad Laboratores),
diluted 1:1000 in PBS-blotto.  The plate was then washed 5 times with PBS, developed
using a TMB Peroxidase EIA Substrate Kit (BioRad Laboratories) and then incubated for
5 min at room temperature.  Absorbances at 655 nm were read after 5 min and 10 min
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using a BioRad model 3550 microplate reader.  The reaction was stopped with 1 N
H2SO4 and the absorbances were read at 450 nm with background subtraction at 655 nm.
Standard Curve Generation via ELISA
Purified Xenopus laevis vitellogenin (138.9 ng/µl) was used as the antigen and
diluted with phosphate-buffered saline (PBS) (136 mM NaCl, 1.5 mM KH2PO4, 8.2 mM
Na2HPO4, 2.7 mM KCl, pH 7.2) to achieve the following concentrations: 4000, 2000,
1000, 900, 800, 700, 600, 500, 400, 300, 250, 200, 125, 100, 62.5, 31.25, 15.63, 7.82,
3.91, and 1.96 ng/well.  Each well of an Immunosorb microtiter-plate (Nunc, Denmark)
then received 100 µl of respective concentration of purified vitellogenin.  PBS alone was
added to wells designated as blanks.  Antigen (i.e. purified vitellogenin) was allowed to
bind to the plate overnight at 4oC in a covered glass dish with water to create a humidity
chamber.  The plate was then washed 5 times with PBS.  Next, 100 µl of PBS-blotto (5 g
nonfat dry milk in 100 ml PBS) was used to block each well for 1 hr at room temperature,
covered, with shaking.  The plate was washed 5 times with PBS and the PBS-blotto was
replaced with 100 µl of PBS-blotto containing primary antibody (polyclonal #498- rabbit
anti-X. laevis vitellogenin), diluted 1:1000 and the plate was incubated 2 hr at room
temperature, covered, with shaking.  The plate was then washed 5 times with PBS and
incubated covered 2 hr on the shaker at room temperature, with the secondary antibody
(goat anti-rabbit immunoglobulin conjugated to horseradish peroxidase; BioRad
Laboratories), diluted 1:1000 in PBS-blotto.  The plate was then washed 5 times with
PBS, developed using a TMB Peroxidase EIA Substrate Kit (BioRad Laboratories) and
then incubated for 5 min at room temperature.  Absorbances at 655 nm were read after 5
min and 10 min using a BioRad model 3550 microplate reader.  The reaction was stopped
36
with 1 N H2SO4 and the absorbances were read at 450 nm with background subtraction at
655 nm.  A standard curve of absorbance (450 nm) versus vitellogenin concentration was
generated and used for serum vitellogenin quantitation.
RNA extraction
Total RNA was isolated using TRIzol Reagent (Invitrogen Life Technologies),
following the manufacturer’s instructions.  Frozen liver sample (50-100 mg) was
homogenized in 1 ml of TRIzol at room temperature using a BioSpec Tissue Tearor
homogenizer (BioSpec Products Inc., Bartlesville, OK).  The homogenate was mixed
with 200 µl of chloroform and centrifuged at 12,000 x g for 15 min at 4oC.  The
supernatant was removed and 500 µl of isopropyl alcohol was added and then centrifuged
at 12,000 x g for 10 min at 4oC.  The resulting RNA pellet was washed with 1000 µl of
75% ethanol, centrifuged at 7000 x g for 5 min at 4oC, air-dried, and resuspended in 100
µl of diethylpyrocarbonate (DEPC)-treated water.  Following a 10 min incubation at 55-
60oC, RNA was quantified using a spectrophotometer (ThermoSpectronic, Genesys 8).
The amount of RNA extracted was determined by ultraviolet light absorption at 260 nm.
RNA samples were stored at –80oC until use.
Selection of primers for polymerase chain reaction (PCR)
PCR primers for Xenopus vitellogenin rt-PCR were selected from the complete
coding sequence for Xenopus laevis vitellogenin (GenBank accession #M18061). Two
sets of primers were devised.  The first sets forward primer corresponds to nucleotides
1769-1793 and has the sequence (5’ to 3’) GCA AGC TTC ACC TTC TCC CAA ATG
(F100).  The reverse primer corresponds to nucleotides 1881-1905 and has the sequence
(5’ to 3’) TTG CTG TAT CGG TAT CCC AGG TTG (R100).  The expected rt-PCR
37
product from this primer pair is 137 base pairs.  The second sets forward primer
corresponds to nucleotides 1647-1671 and has the sequence (5’ to 3’) ATG TTC GCA
CTG AAG TTC GTA TGAT (VTGC).  The reverse primer corresponds to nucleotides
2383-2407 and has the sequence (5’ to 3’) AGT CGT TGG AAT GAT GTG TCG ATA
C (VTGE).  The expected rt-PCR product from this primer pair is 761 base pairs (Selcer
et al., 2001).  Primer pairs were chosen such that the coding region spanned introns in the
genomic vitellogenin sequence (GenBank accession #Y00354).  Primers were devised
and synthesized by Integrated DNA Technologies, Inc. (IDT) (Coralville, IA).
Reverse transcriptase polymerase chain reaction (rt-PCR)
rt-PCR was performed using the SuperScript™ One-Step RT-PCR with
Plantinum®Taq Kit (Invitrogen Life Technologies) following the manufacturers
instructions.  rt-PCR reactions consisted of: 1 µg template RNA, 1 µl VTGC (forward
primer; 150 pmol), 1 µl VTGE (reverse primer; 150 pmol), 1 µl RT/Platinum®Taq Mix,
25 µl 2X reaction mix (a buffer containing 0.4 mM of each dNTP, 2.4 mM MgSO4), and
autoclaved water up to 50 µl.  The PCR reaction was run in a PTC-100 Programmable
Thermal Controller (MJ Research, Inc., Watertown, MA).  The program for amplification
included the reverse transcription step, which consisted of a 30 min hold at 55oC and a 2
min hold at 94oC.  Next, the cDNA was amplified over 30 cycles of:  30 sec 94oC, 1 min
55oC, and 3 min 72 oC.  The PCR reaction was terminated with a final extension of 9 min
at 72oC, and then held at 4oC.  The PCR products were then separated in a 2% agarose gel
containing 5 µl of 1 mg/ml ethidium bromide solution run in 1X TAE running buffer (40
mM Tris-acetate, 2 mM Na2-EDTA-2H2O) for 1 h at 70 volts.  Ten µl of PCR product
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was mixed with 2 µl 10X loading dye (41% w/v Bromophenol blue, 25% w/w Ficoll).  A
100 bp DNA Ladder (Invitrogen Life Technologies) was used as the standard.
Sequencing of PCR product
DNA was prepared for sequencing by extracting the DNA-containing band with a
razor blade and removing the DNA from the gel using GelElute spin columns (Supelco
Inc, Bellefonte, PA).  DNA was then extracted from the resulting supernatant using
phenol-chloroform and precipitated with ethanol.  DNA was sequenced using an ABI 310
automated sequencer, using the same forward and reverse primers used in the rt-PCR for
the cycle sequencing reaction.  Cycle sequencing was performed using an ABI Prism Dye
Terminator Cycling Sequencing Ready Reaction Kit (ABI, Norwalk, CT).
Statistical Analysis
All statistics were performed using the Prism statistical analysis package
(GraphPad, Inc., San Diego, CA).  Comparisons of variables among treatment groups
were made using one-way analysis of variance (ANOVA). Student-Newman-Keuls test
was used for a posteriori comparisons of means. The vitellogenin standard curve was
developed using a non-linear regression model.  Probabilities of p<0.05 were considered
significant.
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Results
Experiment 1: Establish Positive Controls
SDS-PAGE
Differences in serum protein composition were examined by SDS-PAGE (Figure
1) among ethinyl-estradiol injected females (weekly for 3 weeks), 1-week ethinyl-
estradiol (1 mg/ml) injected males, and untreated (negative control) males. There was an
apparent induction of a 200 kDa protein (vitellogenin) by ethinyl-estradiol in both males
and females.  Females (3 week) contained substantially greater amounts of serum
vitellogenin when compared to males (1 week).  Negative control males did not contain
any observable serum vitellogenin.
Western Blot
Western blotting of sera from estrogen-treated and control individuals using
antibody #498 (Selcer et al., 2001) revealed several bands of cross-reactivity (Figure 2).
In estrogen-treated females (3 week) and the estrogen-treated males (1 week) a major
band of cross-reactivity was found at 200 kDa.  Untreated males (negative controls) did
not show cross-reactivity at that position, but did show a band at approximately 50 kDa.
Xenopus laevis Vitellogenin Purification
Serum from a female injected with ethinyl-estradiol and serum from a negative
control male were fractionated on a DEAE chromatography column (Figure 3).   One
major peak was eluted from the DEAE column for the negative control male and two
major peaks were eluted for the estrogen-treated female (Figure 3).  Both peaks were
eluted during the salt gradient (NaCl), with peak one at low salt and peak two at high salt.
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Analysis of the fractions by SDS-PAGE (Figure 4) revealed that the first peak
consisted largely of proteins in the 70 kDa range, likely representing albumin. The
second peak primarily contained a 200 kDa protein.  This peak was considered to be
vitellogenin.
Serum from one estrogen-treated female was used for vitellogenin purification.
The purified vitellogenin was comprised of pooled fractions (#39-46) taken from serum
of the same female, on 3 separate runs.  The pooled vitellogenin containing fractions
were dialyzed, lyophilized, and stored at –20o C for later quantification and standard
curve generation.
Quantification of Purified Vitellogenin Protein Concentration
Protein concentration of the purified vitellogenin was determined by both
Coomassie protein assay and BCA protein assay.  Three milligrams of lyophilized
purified vitellogenin powder was mixed with 7.5 ml of carbonate buffer.  This mixture
was then used in each assay to determine protein concentration.  The Coomassie assay
resulted in a calculated protein concentration of 135.0 ng purified vitellogenin/µl.  The
BCA assay resulted in a calculated protein concentration of 142.7 ng purified
vitellogenin/µl.  Therefore, the average of the two values (138.9 ng/µl) was assigned as
the protein concentration of purified vitellogenin.
Generation of Xenopus laevis Vitellogeninin ELISA Standard Curve
A vitellogenin standard curve was generated using the purified vitellogenin (138.9
ng/µl) as antigen and purified polyclonal #498 as the primary antibody (Figure 5).
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rt-PCR
Hepatic mRNA levels were investigated using rt-PCR.  An abundant PCR product
of the expected size (761 bp) was visible in the lanes containing the products from the
ethinyl-estradiol treated female frog hepatic RNAs (Figure 6), while bands were lacking
at the same position in all but one of the negative control frog lanes (Figure 7).  No bands
were present in the lane containing mRNA from an ethinyl-estradiol treated female
without reverse transcriptase.  This indicates that the observed band is derived from
mRNA rather than DNA.
Sequencing of PCR product
The PCR product from the rt-PCR reaction of ethinyl-estradiol-treated female
frog RNA was extracted and subjected to primer extension sequence analysis.  The
sequence generated was identical to the known complete sequence for Xenopus laevis
vitellogenin cDNA (GenBank assession #M 18061), confirming that the cDNA fragment
generated by the vitellogenin rt-PCR procedure was the intended product.
Experiment 2: Time Course Injection
Coomassie Protein Assay
Serum protein concentrations, determined by Coomassie assay, were compared
among treatment groups (Figure 8).  One-way analysis of variance (ANOVA) revealed
significant differences among groups (F=5.636; 3,16 df; p<0.01).  The only significant
difference found was between 1-week and 4-week males (Student-Newman-Keuls,
p<0.05).
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SDS-PAGE
Differences in serum protein composition were examined by SDS-PAGE between
ethinyl-estradiol injected males and untreated (negative control) males (Figure 9) over a
time course of 4 weeks. The 4-week males contained substantially greater amounts of
serum vitellogenin (200 kDa) when compared to the 1- and 2-week males.  There was no
apparent difference between the 1- and 2-week males.  Negative control males did not
contain any detectable serum vitellogenin; however, negative control males did exhibit a
reduction in a 66 kDa protein.
Western Blot
Western blotting of sera from ethinyl-estradiol treated and untreated (negative
control) males using antibody #498 revealed several bands of cross-reactivity (Figure 10).
In the ethinyl-estradiol treated males a major band was found at 200 kDa.  The 200 kDa
band was more abundant in the 4-week males compared to the 1- and 2-week males.  The
untreated males (negative control males) did not show cross-reactivity at that position
(not shown).
Vitellogenin Concentration
Mean vitellogenin concentrations were determined for each treatment group
(Figure 11) by ELISA using the Xenopus purified vitellogenin standard curve (Figure 5).
One-way analysis of variance (ANOVA) revealed significant differences among
treatment groups (F=30.09; 3, 16 df; p<0.0001).  Control animals, which showed no
detectable vitellogenin, were significantly different from all other groups.  Among
ethinyl-estradiol-treated groups, weeks 1 and 2 did not differ from each other, but both
differed from week 4 animals (Student-Newman-Keuls, p<0.05)
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rt-PCR
Hepatic mRNA levels were investigated in male Xenopus laevis 1-4 weeks after
injection with ethinyl-estradiol  (Figure 12).  An abundant PCR product, corresponding to
the size (761bp) expected for the primer pair used, was visible in all lanes containing the
products from the ethinyl-estradiol treated frog hepatic mRNAs at 1, 2, and 4 weeks after
injection.  This band was lacking in the lane containing 4-week male mRNA without
reverse transcriptase. This indicates that the observed band is derived from mRNA rather
than DNA.
Experiment 3: Time Course Immersion
Coomassie Protein Assay
Serum protein concentrations, determined by Coomassie assay, were compared
among treatment groups (Figure 13).  One-way analysis of variance (ANOVA) revealed
significant differences among groups (F=5.881; 4, 20 df; p<0.003).  Control animals were
not significantly different from vehicle and 1-week animals, but were different from 2-
and 4-week animals.  Week-2 animals also differed significantly from vehicle and 1-
week animals (Student-Newman-Keuls, p<0.05).
SDS-PAGE
Differences in serum protein composition were examined by SDS-PAGE among
males immersed in ethinyl-estradiol, males immersed in vehicle, and untreated (negative
control) males over a time course of 4 weeks (Figure 14).  The 2-week and 4-week males
contained substantially greater amounts of serum vitellogenin when compared to the 1-
week males.  The vehicle and negative control males did not contain any observable
serum vitellogenin.
44
Western Blot
Western blotting of sera from males immersed in ethinyl-estradiol, males
immersed in vehicle, and untreated (negative control) males using antibody #498
revealed cross-reactivity with certain bands (major one at 200 kDa) in the ethinyl-
estradiol-treated males that were not present in the negative control males (Figure 15).
This band had greater abundance in the 4-week and 2-week males compared to the 1-
week males.
Vitellogenin Concentration
Mean vitellogenin concentrations were determined for each treatment group
(Figure 16) by ELISA using the Xenopus purified vitellogenin standard curve.  One-way
analysis of variance (ANOVA) revealed significant differences among treatment groups
(F=130.7; 4, 20 df; p<0.0001).  Control, vehicle, and 1-week animals, which showed no
detectable vitellogenin, were significantly different from all other groups.  Weeks 2 and 4
also differed significantly between each other (Student-Newman-Keuls, p<0.05)
rt-PCR
Hepatic mRNA levels of male Xenopus laevis were investigated 1-4 weeks after
immersion in ethinyl-estradiol (Figure 17).  An abundant PCR product, corresponding to
the size (761 bp) expected for the primer pair used, was visible in all lanes containing the
products from the ethinyl-estradiol treated frog hepatic mRNAs, while bands were
lacking at the same position in the lane containing 4-week mRNA without reverse
transcriptase.  This indicates that the observed band is derived from mRNA rather than
DNA.
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Experiment 4: Primed Injection
Coomassie Protein Assay
Serum protein concentrations, determined by Coomassie assay, were compared
among treatment groups (Figure 18).  One-way analysis of variance (ANOVA) revealed
significant differences among groups (F=10.38; 8, 20 df; p<0.0001).  The 2-week vehicle,
4, 8, and 12 hour unprimed animals were not significantly different from each other;
however, they were significantly different from all of the primed treatment groups.  There
were no significant differences among the primed treatment groups (Student-Newman-
Keuls, p<0.05).
SDS-PAGE
Differences in serum protein composition were examined by SDS-PAGE among
primed and unprimed males injected with ethinyl-estradiol, 2-week vehicle males, and
untreated (negative control) males (Figure 19), to ascertain the effects of priming on
vitellogenin (200 kDa) induction.  The primed males (2-week primed, 4, 8, and 12 hour
primed) contained substantially greater amounts of serum vitellogenin when compared to
the unprimed males (4, 8, and 12 hour).  The vehicle and negative control males did not
contain any detectable serum vitellogenin.
Western Blot
Western blotting of sera from primed and unprimed males injected with ethinyl-
estradiol and vehicle males using polyclonal antibody #498 (Figure 20), revealed cross-
reactivity with certain bands (major one at 200 kDa) in all primed males.  The unprimed
males and 2-week vehicle males did not show cross-reactivity at that position.
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rt-PCR
Hepatic mRNA levels of male Xenopus laevis were investigated at various times
after injection with ethinyl-estradiol (Figure 21).  An abundant PCR product,
corresponding to the size (761 bp) expected for the primer pair used, was visible in the
lanes containing the products from hepatic mRNAs of all primed individuals.  Messenger
RNA levels are not as elevated in the unprimed animals and are shown to increase from 4
to 8 to 12 hours in unprimed animals.
Experiment 5: Dose Response Injection
Coomassie Protein Assay
Serum protein concentrations, determined by Coomassie assay, were compared
among treatment groups (Figure 22).  One-way analysis of variance (ANOVA) revealed
no significant differences among groups (F=2.103; 4, 20 df; p=0.1183).
SDS-PAGE
Differences in serum protein composition were examined by SDS-PAGE between
males injected with various doses of ethinyl-estradiol ranging from 1000 µg/kg (high-
dose)-0.001 µg/kg (very-low-dose) and vehicle control males (Figure 23).  High-dose
males had abundant amounts of serum vitellogenin, while only 2 of the 5 medium-dose
males had detectable serum vitellogenin.  The remaining medium-dose males, low-dose
males, very-low-dose males, and vehicle control males did not contain any observable
serum vitellogenin.
Western Blot
Western blotting of sera from males injected with various doses of ethinyl-
estradiol ranging from 1000µg/kg (high dose)-0.001µg/kg (very low dose) and vehicle
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control males using polyclonal antibody #498 (Figure 24), revealed cross-reactivity with
certain bands (major one at 200kDa) in high-dose and medium-dose males.  The low-
dose males, very-low-dose males, and vehicle control males did not show cross-reactivity
at that position.
Vitellogenin Concentration
Mean vitellogenin concentrations were determined for each treatment group using
the Xenopus purified vitellogenin standard curve  (Figure 25).  One-way analysis of
variance (ANOVA) revealed significant differences among treatment groups (F=139.1; 4,
19 df; p<0.0001).  Vehicle, very-low-dose, low-dose, and medium-dose animals, which
showed no observable vitellogenin, were significantly different from high-dose animals
(Student-Newman-Keuls, p<0.05).
rt-PCR
Hepatic mRNA levels in male Xenopus were investigated after injection with
ethinyl-estradiol at various doses (Figure 26).  An abundant PCR product, corresponding
to the size (761bp) expected for the primer pair used, was visible in the lanes containing
the products from the high-dose and medium-dose frog hepatic mRNAs, while
substantially less product was observed in the lanes containing the products from the low-
dose.  No visible bands were present in the lanes containing the products from the very-
low-dose frog hepatic mRNAs.
Experiment 6: Dose Response Immersion
Coomassie Protein Assay
Serum protein concentrations, determined by Coomassie assay, were compared
among treatment groups (Figure 27).  One-way analysis of variance (ANOVA) revealed
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significant differences among groups (F=25.61; 5, 24 df; p<0.0001).   The very-high-dose
(1µg/L) animals were significantly different from all other treatment groups.  Vehicle
animals were also significantly different from all other treatment groups except the low-
dose (0.001µg/L) animals.  Very-low-dose (0.0001µg/L), low-dose (0.001µg/L),
medium-dose (0.01µg/L), and high-dose (0.1µg/L) animals were not significantly
different from each other (Student-Newman-Keuls, p<0.05).
SDS-PAGE
Differences in serum protein composition were examined by SDS-PAGE between
males immersed in various doses of ethinyl-estradiol and males immersed in vehicle
(Figure 28a and 28b).  The very-high-dose males and high-dose males contained large
amounts of serum vitellogenin.  The medium-dose males, low-dose-males, very-low-dose
males, and vehicle control males did not contain any observable serum vitellogenin.
Western Blot
Western blotting of sera from males immersed in various doses of ethinyl-
estradiol and males immersed in vehicle using antibody #498 (Figure 29), revealed cross-
reactivity with certain bands (major one at 200 kDa) in the very-high-dose males and the
high-dose males.  The medium-dose, low-dose, very-low-dose, and vehicle control males
did not show cross-reactivity at that position.
Vitellogenin Concentration
 Mean vitellogenin concentrations were determined for each treatment group
using the Xenopus purified vitellogenin standard curve (Figure 30).  One-way analysis of
variance (ANOVA) revealed significant differences among treatment groups (F=97.88; 5,
23 df; p<0.0001).  The very-high-dose animals were significantly different from all other
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groups, which were not significantly different from each other (Student-Newman-Keuls,
p<0.05).
rt-PCR
Hepatic mRNA levels of male Xenopus laevis were investigated after immersion
in ethinyl-estradiol at various doses (Figure 31).  An abundant PCR product,
corresponding to the size (761bp) expected for the primer pair used, was visible for the
lanes containing the products from the very-high-dose and high-dose frog hepatic
mRNAs, while less intense bands were observed for the medium-dose and low-dose frog
hepatic mRNAs.  A very faint band was visible in the lane containing the product from
the very-low-dose frogs.
Experiment 7: Xenobiotic Immersion
Coomassie Protein Assay
Serum protein concentrations, determined by Coomassie assay, were compared
among treatment groups (Figure 32).  One-way analysis of variance (ANOVA) revealed
significant differences among groups (F=3.9531; 5, 27 df; p<0.01).  Octylphenol animals
were significantly different from atrazine and nonylphenol animals, which were not
significantly different from each other.  No significant differences were observed
between any other groups (Student-Newman-Keuls, p<0.05).
SDS-PAGE
Differences in serum protein composition were examined by SDS-PAGE among
males immersed in different xenobiotic estrogens (atrazine, octylphenol, nonylphenol,
and bisphenol-A), males immersed in vehicle, and untreated (negative control) males
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(Figure 33).  A 200 kDa band was lacking in all animals, indicating an absence of
vitellogenin.  Western blotting (not shown) confirmed these results.
Indirect ELISA
Mean serum vitellogenin concentrations were compared among treatment groups
using an indirect ELISA (Figure 34).  One-way analysis of variance (ANOVA) revealed
no significant differences among groups (F=2.075; 5, 24df; p=0.1039).
rt-PCR
Hepatic mRNA levels of male Xenopus laevis were investigated after immersion
in various xenobiotic estrogens (Figure 35).  Before the hepatic mRNA’s from frogs
treated with xenobiotic estrogens were subjected to rt-PCR, an ethinyl-estradiol injected
female was run as a positive control for the new primer pair. An abundant PCR product,
corresponding to the size (137 bp) expected for the primer pair used, was visible in Panel
A in the lane containing the product from the ethinyl-estradiol injected female frog
hepatic RNA.  Panels B-E represent hepatic mRNAs from frogs treated with atrazine,
nonylphenol, octylphenol, and bisphenol-A.  The gels represent 4 individuals from each
treatment group, showing variability in response between individuals.  Males treated with
octyphenol and bisphenol-A have a substantially greater product than those males
immersed in atrazine and nonylphenol.  However, the product bands in all of the
xenobiotic treatment groups are substantially less abundant than bands observed for
ethinyl-estradiol treated animals.  Panel F represents hepatic mRNAs from untreated
negative control frogs.  Surprisingly, 1 out of 8 individuals had a visible band at 137 bp,
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Figure 1.  Denaturing polyacrylamide gel electrophoresis (SDS-PAGE) of sera from
adult Xenopus laevis after injection with ethinyl-estradiol.  Negative control males
were left untreated.  Estrogen-treated females were injected (i.p.) weekly for 3 weeks
with 0.25 cc ethinyl-estradiol (1 mg/ml) dissolved in propylene glycol, and estrogen-
treated males were injected (i.p.) one time with 0.20 cc ethinyl-estradiol (1 mg/ml)
dissolved in propylene glycol and sacrificed after 1-week. Lane assignments are as
follows: 1=Sigma molecular weight standard (S); 2,6,12=negative control male (C); 3, 7,
10=estrogen-treated female (Ef): 4, 8, 14=estrogen-treated male (Em); 5=Kaleidoscope
molecular weight standard (K); and 9, 11, 13, 15=blank.  Arrow at approximately 200
kDa indicates the expected molecular weight of vitellogenin (VTG). Sera were separated
on a 4 to 15% polyacrylamide gradient gel and stained with Coomassie blue. See
methods for treatment regimens (Experiment 1 and 2).  [Representative individuals are
shown, 5 individuals comprised each treatment group; therefore, some may not be
shown]
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Figure 2.  Western Blot of sera from adult male Xenopus laevis after injection with
ethinyl-estradiol. Negative control males were left untreated.  Estrogen-treated females
were injected (i.p.) weekly for 3 weeks with 0.25 cc ethinyl-estradiol (1 mg/ml) dissolved
in propylene glycol and estrogen-treated males were injected (i.p.) one time with 0.20 cc
ethinyl-estradiol (1 mg/ml) dissolved in propylene glycol and sacrificed after 1 week.
Primary antibody polyclonal #498 (rabbit anti-Xenopus laevis vitellogenin) was used at a
1:1000 dilution followed by secondary antibody, goat anti-rabbit IgG-HRP, which was
also diluted 1:1000. Lane assignments are as follows:  1,12=Sigma molecular weight
marker (S); 2,6,9,13=negative control (C); 3,7,10,14=estrogen-treated female (Ef);
4,8,11,15=estrogen-treated male (Em); and 5=Kaleidoscope molecular weight standard
(K). Arrow at approximately 200 kDa indicates the expected molecular weight of
vitellogenin (VTG).   See methods for treatment regimens (Experiment 1 and 2).
[Representative individuals are shown, 5 individuals comprised each treatment group;
therefore, some may not be shown]
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Figure 3.  DEAE chromatography protein profile of sera from negative control male
and estrogen-treated female Xenopus laevis.  The negative control male was untreated.
The estrogen-treated female was injected (i.p.) with 0.25 cc ethinyl-estradiol (1 mg/ml)
weekly for 3 weeks.  Serum proteins were separated on a DEAE-MacroPrep column
using a Bio-Rad Econo Chromatography System.  Proteins were subsequently measured
by Coomassie assay for each fraction.
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Figure 4.  Denaturing polyacrylamide gel electrophoresis (SDS-PAGE) of DEAE
fractions of sera from a negative control male and an estrogen-treated female.  The
negative control male was untreated.  The estrogen-treated female was injected (i.p.)
weekly for 3 weeks with 0.25 cc ethinyl-estradiol (1 mg/ml) dissolved in propylene
glycol.  Serum proteins from both animals were separated on a DEAE-MacroPrep
column using a Bio-Rad Econo Chromatography System and certain fractions
(4,17,23,24,29,30, and 31) were chosen for further examination (based on the DEAE
protein profile in Figure 3).  Lane assignments are as follows: 1,3,5,7,10,12,14=negative
control male (C); 2,4,6,8,11,13,15=estrogen-treated female (Ef); and 9=Sigma molecular
weight marker (S). Arrow at approximately 200 kDa indicates the expected molecular
weight of vitellogenin (VTG). Sera were separated on a 4 to 15% polyacrylamide
gradient gel and stained with Coomassie blue.  See methods from treatment regimens
(Experiment 1 and 2).
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Figure 5.  Standard curve for Xenopus laevis vitellogenin ELISA.  Purified
vitellogenin (135.9 ng/µl) was used as antigen and detected with primary antibody
polyclonal #498 (rabbit anti-Xenopus laevis vitellogenin) at a 1:1000 dilution.  Secondary
antibody (goat anti-rabbit IgG HRP) was also used at a 1:1000 dilution.  Data were taken
from two separate assays.  Each individual point is the average of triplicate samples.
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Figure 6.  Detection of hepatic vitellogenin mRNA in ethinyl-estradiol-injected
female Xenopus laevis using rt-PCR.  rt-PCR reactions were performed using total
hepatic RNA extracts (1 µg RNA/reaction) from female Xenopus laevis injected (i.p.)
weekly for 3 weeks with 0.25 cc ethinyl-estradiol (1 mg/ml).  Vitellogenin-specific
primers VTGC and VTGE were used.  rt-PCR reaction products were separated on a 2%
agarose gel and stained with ethidium bromide.  Lane assignments are as follows:
1,2,3=ethinyl-estradiol-treated females (Positive Control); 4=100bp DNA ladder (L); and
5=positive control female minus reverse transcriptase (-RT).  Arrow with 761 bp shows
the expected product size for vitellogenin mRNA using this primer pair.  See methods for
treatment regimen (Experiment 1).  [Each lane represents a different individual].
    1          2        3        4        5
   Positive Control       L     -RT
761 bp
bp
2072
1500
600
57
Figure 7.  Detection of hepatic vitellogenin mRNA in negative control male Xenopus
laevis using rt-PCR. rt-PCR reactions were performed using total hepatic RNA extracts
(1 µg RNA/reaction) from untreated male Xenopus laevis.  Vitellogenin-specific primers
VTGC and VTGE were used.  rt-PCR reaction products were separated on a 2% agarose
gel and stained with ethidium bromide.  Lane assignments are as follows: 1-8=untreated
males (Negative Control); 9=negative control male minus reverse transcriptase (-RT);
and 10=100 bp DNA ladder (L).  Arrow with 761 bp shows the expected product size for
vitellogenin mRNA using this primer pair.  See methods for treatment regimens
(Experiment 7).  [Each lane represents a separate individual].
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Figure 8.  Protein concentration of sera from adult male Xenopus laevis 1-4 weeks
after injection with ethinyl-estradiol.  Control animals (C) were left untreated.
Treatment animals were injected (i.p.) one time with 0.20 cc ethinyl-estadiol (1 mg/ml)
dissolved in propylene glycol and sacrificed at 1, 2, or 4 weeks. Bars represent mean (+/-
standard error) protein concentration of five frogs per group calculated from a Coomassie
assay.  Different letters above bars indicate significant differences between groups
(Student-Newman-Keuls, p<0.05). See methods for treatment regimens (Experiment 2).
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Figure 9.  Denaturing polyacrylamide gel electrophoresis (SDS-PAGE) of sera from
adult male Xenopus laevis 1-4 weeks after injection with ethinyl-estradiol. Control
animals were left untreated.  Treatment animals were injected (i.p.) one time with 0.20 cc
ethinyl-estadiol (1 mg/ml) dissolved in propylene glycol and sacrificed at 1, 2, or 4
weeks.  Lane assignments are as follows: 1,2=negative control (C); 3,4=1 week; 5,6=2
week; 7=Sigma molecular weight standard (S); and 8,9=4 week. Arrow at approximately
200 kDa indicates the expected molecular weight of vitellogenin. Sera were separated on
a 4 to 15% polyacrylamide gradient gel and stained with Coomassie blue. See methods
for treatment regimens (Experiment 2). [Representative individuals are shown, 5
individuals comprised each treatment group; therefore, some may not be shown]
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Figure 10.  Western Blot of sera from adult male Xenopus laevis 1-4 weeks after
injection with ethinyl-estradiol.  Treatment animals were injected (i.p.) one time with
0.20 cc ethinyl-estadiol (1 mg/ml) dissolved in propylene glycol and sacrificed at 1, 2, or
4 weeks.  Primary antibody polyclonal #498 (rabbit anti-Xenopus laevis vitellogenin) was
used at a 1:1000 dilution followed by secondary antibody, goat anti-rabbit IgG-HRP,
which was also diluted 1:1000. Lane assignments are as follows:  1,2,3=1 week; 4,5,6=2
week; and 7,8,9=4 week. Arrow at approximately 200 kDa indicates the expected
molecular weight of vitellogenin.  See methods for treatment regimens (Experiment 2).
[Representative individuals are shown, 5 individuals comprised each treatment group;
therefore, some may not be shown]
 1    2    3     4    5    6    7    8    9
     1wk            2wk           4wk
    VTG
MW (kDa)
210
135
38.7
61
Figure 11.  Vitellogenin concentration of sera from adult male Xenopus laevis 1-4
weeks after injection with ethinyl-estradiol. Control animals (C) were left untreated.
Treatment animals were injected (i.p.) one time with 0.20 cc ethinyl-estadiol (1 mg/ml)
dissolved in propylene glycol and sacrificed at 1, 2, or 4 weeks. Bars represent mean (+/-
standard error) serum vitellogenin concentrations of five frogs per group calculated from
the vitellogenin ELISA standard curve (Figure 5).  Different letters above bars indicate
significant differences between groups (Student-Newman-Keuls, p<0.05). See methods
for treatment regimens (Experiment 2).
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Figure 12.  Detection of hepatic vitellogenin mRNA using rt-PCR in male Xenopus
laevis 1-4 weeks after injection with ethinyl-estradiol. rt-PCR reactions were
performed using total hepatic RNA extracts (1 µg RNA/reaction) from animals injected
(i.p.) one time with 0.20 cc ethinyl-estadiol (1mg/ml) dissolved in propylene glycol, then
sacrificed at 1, 2, or 4 weeks.  Vitellogenin-specific primers VTGC and VTGE were
used.  rt-PCR reaction products were separated on a 2% agarose gel and stained with
ethidium bromide.  Lane assignments are as follows: 1,4=1 week; 2,5=2 week; 3,6=4
week; and 7=4 week minus reverse transcriptase (-RT).  Arrow with 761 bp shows the
expected product size for vitellogenin mRNA with this primer pair.  See methods for
treatment regimens (Experiment 2).  [Each lane represents a different individual].
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Figure 13.  Protein concentration of sera from adult male Xenopus laevis 1-4 weeks
after immersion in ethinyl-estradiol.  Negative controls (C) were left untreated, while
vehicle controls (V) were immersed in methanol (0.1%).  Treatment animals were
immersed in ethinyl-estradiol (1 µg/L) dissolved in methanol and sacrificed at 1, 2, or 4
weeks. Bars represent mean (+/- standard error) protein concentration of five frogs per
group calculated from a Coomassie assay.  Different letters above bars indicate
significant differences between groups (Student-Newman-Keuls, p<0.05). See methods
for treatment regimens (Experiment 3).
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Figure 14.  Denaturing polyacrylamide gel electrophoresis (SDS-PAGE) of sera
from adult male Xenopus laevis 1-4 weeks after immersion in ethinyl-estradiol.
Negative controls were left untreated, while vehicle controls were immersed in methanol
(0.1%).  Treatment animals were immersed in ethinyl-estradiol (1 µg/L) dissolved in
methanol and sacrificed at 1, 2, or 4 weeks. Lane assignments are as follows:
1,2,3=negative control (C); 4,5,6=vehicle control (V); 7,12=Sigma molecular weight
standard; 8,9=1 week; 10,11=2 week; and 13,14=4 week. Arrow at approximately 200
kDa indicates the expected molecular weight of vitellogenin.  Sera were separated on a 4
to 15% polyacrylamide gradient gel and stained with Coomassie blue.  See methods for
treatment regimens (Experiment 3). [Representative individuals are shown, 5 individuals
comprised each treatment group; therefore, some may not be shown]
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Figure 15.  Western Blot of sera from adult male Xenopus laevis 1-4 weeks after
immersion in ethinyl-estradiol.  Negative controls were left untreated, while vehicle
controls were immersed in methanol (0.1%).  Treatment animals were immersed in
ethinyl-estradiol (1 µg/L) dissolved in methanol and sacrificed at 1, 2, or 4 weeks.
Primary antibody polyclonal #498 (rabbit anti- Xenopus laevis vitellogenin) was used at a
1:1000 dilution followed by secondary antibody, goat anti-rabbit IgG-HRP, which was
also diluted 1:1000.  Lane assignments are as follows:  1=negative control (C);
2,3=vehicle control (V); 4=Sigma molecular weight standard (S); 5,6,7= 1 week (1);
8=Kaleidoscope molecular weight standard (K); 9,10,11=2 week (2); and 12,13,14=4
week (4). Arrow at approximately 200 kDa indicates the expected molecular weight of
vitellogenin.  See methods for treatment regimens (Experiment 3). [Representative
individuals are shown, 5 individuals comprised each treatment group; therefore, some
may not be shown]
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Figure 16.  Vitellogenin concentration of sera from adult male Xenopus laevis 1-4
weeks after immersion in ethinyl-estradiol. Negative controls (C) were left untreated,
while vehicle controls (V) were immersed in methanol (0.1%).  Treatment animals were
immersed in ethinyl-estradiol (1 µg/L) dissolved in methanol and sacrificed at 1, 2, or 4
weeks. Bars represent mean (+/- standard error) serum vitellogenin concentrations of five
frogs per group calculated from the vitellogenin ELISA standard curve (Figure 5).
Different letters above bars indicate significant differences between groups (Student-
Newman-Keuls, p<0.05). See methods for treatment regimens (Experiment 3).
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Figure 17.  Detection of hepatic vitellogenin mRNA using rt-PCR in male Xenopus
laevis after 1-4 weeks of immersion in ethinyl-estradiol. rt-PCR reactions were
performed using total hepatic RNA extracts (1 µg RNA/reaction) from animals immersed
in ethinyl-estradiol (1 µg/L) dissolved in methanol (0.1%), then sacrificed at 1, 2, or 4
weeks.  Vitellogenin-specific primers VTGC and VTGE were used.  rt-PCR reaction
products were separated on a 2% agarose gel and stained with ethidium bromide.  Lane
assignments are as follows: 1,4=1 week; 2,5=2 week; 3,6=4 week; and 7=4 week minus
reverse transcriptase (-RT).  Arrow with 761 bp show the expected product size for
vitellogenin mRNA with this primer pair.  See methods for treatment regimens
(Experiment 3).  [Each lane represents a different individual].
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Figure 18.  Protein concentration of sera from adult male Xenopus laevis after
injection with ethinyl-estradiol for various times.  Two-week primed animals (P) were
injected (i.p.) one time with 0.20 cc ethinyl-estradiol (1 mg/ml) dissolved in propylene
glycol and sacrificed after 2 weeks.  Two-week vehicles (V) were injected (i.p.) one time
with 0.20 cc propylene glycol and sacrificed after 2 weeks. Unprimed animals (4U, 8U,
12U) were injected with 0.20 cc propylene glycol, left without further treatment for 30
days, injected with 0.20 cc ethinyl-estradiol (1 mg/ml) dissolved in propylene glycol, and
sacrificed at 4, 8, or 12 hours. Primed animals (0P, 4P, 8P, 12P) were injected with 0.20
cc ethinyl-estradiol (1 mg/ml) dissolved in propylene glycol, left without further
treatment for 30 days, re-injected with 0.20 cc ethinyl-estradiol (1 mg/ml) (except 0-hour
primed, which were not re-injected), and sacrificed at 4, 8, or 12 hours. Bars represent
mean (+/- standard error) protein concentration of three frogs per group calculated from a
Coomassie assay.  Different letters above bars indicate significant differences between
groups (Student-Newman-Keuls, p<0.05). See methods for treatment regimens
(Experiment 4).
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Figure 19.  Denaturing polyacrylamide gel electrophoresis (SDS-PAGE) of sera
from adult male Xenopus laevis after injection with ethinyl-estradiol for various
times.  Two-week primed animals were injected (i.p.) one time with 0.20 cc ethinyl-
estradiol (1 mg/ml) dissolved in propylene glycol and sacrificed after 2 weeks.  Two-
week vehicles were injected (i.p.) one time with 0.20 cc propylene glycol and sacrificed
after 2 weeks.  Primed animals were injected (i.p.) with 0.20 cc ethinyl-estradiol (1
mg/ml) dissolved in propylene glycol, left without further treatment for 30 days, re-
injected with 0.20 cc ethinyl-estradiol (1 mg/ml) (except 0-hour primed, which were not
re-injected), and sacrificed at 4, 8, or 12 hours.  Unprimed animals were injected with
0.20 cc propylene glycol, left without further treatment for 30 days, injected with 0.20 cc
ethinyl-estradiol (1 mg/ml) dissolved in propylene glycol, and sacrificed at 4, 8, or 12
hours.  Lane assignments are as follows: 1,3=2-week primed (P); 2,4=2-week vehicle
(V); 5=Sigma molecular weight standard (S); 6=0-hour primed (0P); 7=4-hour primed
(4P); 8=4-hour unprimed (4U); 9=8-hour primed (8P); 10=8-hour unprimed (8U); 11=12-
hour primed (12P); and 12=12-hour unprimed (12U). Arrow at approximately 200 kDa
indicates the expected molecular weight of vitellogenin. Sera were separated on a 4 to
15% polyacrylamide gradient gel and stained with Coomassie blue. See methods for
treatment regimens (Experiment 4). [Representative individuals are shown, 3 individuals
comprised each treatment group; therefore, some may not be shown]
 1   2    3   4    5   6    7   8   9  10  11 12
  P    V     P    V      S    0P   4P   4U  8P  8U  12P 12U
MW (kDa)
205
116
36
    VTG
66
70
Figure 20.  Western Blot of sera from adult male Xenopus laevis after injection with
ethinyl-estradiol for various times.  Two-week primed animals were injected (i.p.) one
time with 0.20 cc ethinyl-estradiol (1 mg/ml) dissolved in propylene glycol and sacrificed
after 2 weeks.  Two-week vehicles were injected (i.p.) one time with 0.20 cc propylene
glycol and sacrificed after 2 weeks.  Primed animals were injected with 0.20 cc ethinyl-
estradiol (1 mg/ml) dissolved in propylene glycol, left without further treatment for 30
days, re-injected with 0.20 cc ethinyl-estradiol (1 mg/ml) (except 0-hour primed, which
were not re-injected), and sacrificed at 4, 8, or 12 hours.  Unprimed animals were injected
with 0.20 cc propylene glycol, left without further treatment for 30 days, injected with
0.20 cc ethinyl-estradiol (1 mg/ml) dissolved in propylene glycol, and sacrificed at 4, 8,
or 12 hours. Primary antibody polyclonal #498 (rabbit anti-Xenopus laevis vitellogenin)
was used at a 1:1000 dilution followed by secondary antibody, goat anti-rabbit IgG-HRP,
which was also diluted 1:1000.  Lane assignments are as follows:  1,3=2-week primed
(P); 2,4= 2-week vehicle (V); 5= Kaleidoscope molecular weight standard (K); 6=0-hour
primed (0P); 7=4-hour primed (4P); 8=4-hour unprimed (4U); 9=8-hour primed (8P);
10=8-hour unprimed (8U); 11=12-hour primed (12P); and 12=12-hour unprimed (12U).
Arrow at approximately 200 kDa indicates the expected molecular weight of vitellogenin.
See methods for treatment regimens (Experiment 4). [Representative individuals are
shown, 3 individuals comprised each treatment group; therefore, some may not be
shown]
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Figure 21.  Detection of hepatic vitellogenin mRNA using rt-PCR in male Xenopus
laevis after injection with ethinyl-estradiol for various times.  rt-PCR reactions were
performed using total hepatic RNA extracts (1 µg RNA/reaction) from 2-week primed
animals injected (i.p.) one time with 0.20 cc ethinyl-estradiol (1 mg/ml) dissolved in
propylene glycol and sacrificed after 2 weeks; primed animals injected (i.p.) one time
with 0.20 cc ethinyl-estradiol (1 mg/ml) dissolved in propylene glycol, left without
further treatment for 30 days, re-injected with 0.20 cc ethinyl-estradiol (1 mg/ml) (except
0-hour primed, which were not re-injected), and sacrificed at 4, 8, or 12 hours; and
unprimed animals injected (i.p.) one time with 0.20 cc propylene glycol, left without
further treatment for 30 days, injected with 0.20 cc ethinyl-estradiol (1 mg/ml) dissolved
in propylene glycol, and sacrificed at 4, 8, or 12 hours.  Vitellogenin-specific primers
VTGC and VTGE were used.  Rt-PCR reaction products were separated on a 2% agarose
gel and stained with ethidium bromide.  Lane assignments are as follows:  1=2-week
primed (P); 2=4-hour unprimed (4U); 3=8-hour unprimed (8U); 4=12-hour unprimed
(12U); 5=0-hour primed (0P); 6=4-hour primed (4P); 7=8-hour primed (8P); and 8=12-
hour primed (12P).  Arrow with 761 bp shows the expected product size for vitellogenin
mRNA using this primer pair.  See methods for treatment regimens (Experiment 4).
[Each lane represents a different individual].
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Figure 22.  Protein concentration of sera from adult male Xenopus laevis after
injection with ethinyl-estradiol at various doses.  Treatment animals were injected
(i.p). one time with 0.20 cc of 0, 0.001, 0.1, 10, or 1000 µg/kg ethinyl-estradiol dissolved
in propylene glycol. Bars represent mean (+/- standard error) protein concentration of
five frogs per group calculated from a Coomassie assay.  Different letters above bars
indicate significant differences between groups (Student-Newman-Keuls, p<0.05). See
methods for treatment regimens (Experiment 5).
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Figure 23.  Denaturing polyacrylamide gel electrophoresis (SDS-PAGE) of sera
from adult male Xenopus laevis after injection with ethinyl-estradiol at various
doses.   Treatment animals were injected (i.p.) one time with 0.20 cc of 0, 0.001, 0.1, 10,
or 1000 µg/kg ethinyl-estradiol dissolved in propylene glycol.  Lane assignments are as
follows: 1,2,3=0 µg/kg; 4,5,6=0.001 µg/kg; 7=Sigma molecular weight marker (S);
8,9=0.1 µg/kg; 10,11=10 µg/kg; 12=blank (B); and 13,14=1000 µg/kg. Arrow at
approximately 200 kDa indicates the expected molecular weight of vitellogenin. Sera
were separated on a 4 to 15% polyacrylamide gradient gel and stained with Coomassie
blue. See methods for treatment regimens (Experiment 5). [Representative individuals are
shown, 5 individuals comprised each treatment group; therefore, some may not be
shown]
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Figure 24.  Western Blot of sera from adult male Xenopus laevis after treatment
injection with ethinyl-estradiol at various doses.  Treatment animals were injected
(i.p.) one time with 0.20 cc of 0, 0.001, 0.1, 10, or 1000 µg/kg ethinyl-estradiol dissolved
in propylene glycol.  Primary antibody polyclonal #498 (rabbit anti-Xenopus laevis
vitellogenin) was used at a 1:1000 dilution followed by secondary antibody, goat anti-
rabbit IgG-HRP, which was also diluted 1:1000.  Lane assignments are as follows:  1,2=0
µg/kg; 3=Kaleidoscope molecular weight standard (K); 4,5,6=0.001 µg/kg; 7,8,9=0.1
µg/kg; 10,11,12=10 µg/kg; and 13,14,15=1000 µg/kg. Arrow at approximately 200 kDa
indicates the expected molecular weight of vitellogenin.  See methods for treatment
regimens (Experiment 5). [Representative individuals are shown, 5 individuals comprised
each treatment group; therefore, some may not be shown]
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Figure 25.  Vitellogenin concentration of sera from adult male Xenopus laevis after
injection with ethinyl-estradiol at various doses. Treatment animals were injected (i.p.)
one time with 0.20 cc of 0, 0.001, 0.1, 10, or 1000 µg/kg ethinyl-estradiol dissolved in
propylene glycol.  Bars represent mean (+/- standard error) serum vitellogenin
concentrations of five frogs per group calculated from the vitellogenin ELISA standard
curve (Figure 5).  Different letters above bars indicate significant differences between
groups (Student-Newman-Keuls, p<0.05).  See methods for treatment regimens
(Experiment 5).
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Figure 26.  Detection of hepatic vitellogenin mRNA using rt-PCR in male Xenopus
laevis after injection with ethinyl-estradiol at various doses.  rt-PCR reactions were
performed using total hepatic RNA extracts (1 µg/reaction) from animals injected (i.p.)
one time with 0.20 cc of 0.001, 0.1, 10, or 1000 µg/kg ethinyl-estradiol dissolved in
propylene glycol.  Vitellogenin-specific primers VTGC and VTGE were used.  Rt-PCR
reaction products were separated on a 2% agarose gel and stained with ethidium bromide.
Lane assignments are as follows:  Panel A: 1-5=0.001 µg/kg; Panel B: 1-5=0.1 µg/kg;
Panel C: 1-5=10 µg/kg; and Panel D: 1-5=1000 µg/kg.  Arrow with 761 bp shows the
expected product size for vitellogenin mRNA using this primer pair.  See methods for
treatment regimens (Experiment 5).  [Each lane represents a different individual].
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Figure 27.  Protein concentration of sera from adult male Xenopus laevis after
immersion in ethinyl-estradiol at various doses.  Treatment animals were immersed in
0, 0.0001, 0.001, 0.01, 0.1, 1.0 µg/L ethinyl-estradiol dissolved in methanol (0.1%). Bars
represent mean (+/- standard error) protein concentration of five frogs per group
calculated from a Coomassie assay.  Different letters above bars indicate significant
differences between groups (Student-Newman-Keuls, p<0.05). See methods for treatment
regimens (Experiment 6).
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Figure 28a.  Denaturing polyacrylamide gel electrophoresis (SDS-PAGE) of sera
from adult male Xenopus laevis after immersion in ethinyl-estradiol at various
doses. Treatment animals were immersed in 0, 0.0001, or 0.001 µg/L ethinyl-estradiol
dissolved in methanol (0.1%).  Lane assignments are as follows: 1,2=0 µg/L; 3=Sigma
molecular weight standard (S); 4,5,6,7=0.0001 µg/L; and 8,9,10,11=0.001 µg/L. Arrow at
approximately 200 kDa indicates the expected molecular weight of vitellogenin. Sera
were separated on a 4 to 15% polyacrylamide gradient gel and stained with Coomassie
blue. See methods for treatment regimens (Experiment 6). [Representative individuals are
shown, 5 individuals comprised each treatment group; therefore, some may not be
shown]
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Figure 28b.  Denaturing polyacrylamide gel electrophoresis (SDS-PAGE) of sera
from adult male Xenopus laevis after immersion in ethinyl-estradiol at various
doses. Treatment animals were immersed in 0.01, 0.1, or 1.0 µg/L ethinyl-estradiol
dissolved in methanol (0.1%).  Lane assignments are as follows: 1,2,3,4=0.01 µg/L;
5=Sigma molecular weight standard (S); 6,7,8,9=0.1 µg/L; and 10,11,12,13=1.0 µg/L.
Arrow at approximately 200 kDa indicates the expected molecular weight of vitellogenin.
Sera were separated on a 4 to 15% polyacrylamide gradient gel and stained with
Coomassie blue. See methods for treatment regimens (Experiment 6). [Representative
individuals are shown, 5 individuals comprised each treatment group; therefore, some
may not be shown]
       1    2    3   4   5    6   7   8   9  10 11 12 13
              0.01        S          0.1               1.0Dose (µg/L)
MW (kDa)
205
116
36
66
    VTG
80
Figure 29.  Western Blot of sera from adult male Xenopus laevis after immersion in
ethinyl-estradiol at various doses.  Treatment animals were immersed in 0, 0.0001,
0.001, 0.01, 0.1, or 1.0 µg/L ethinyl-estradiol dissolved in methanol (0.1%).  Primary
antibody polyclonal #498 (rabbit anti- Xenopus laevis vitellogenin) was used at a 1:1000
dilution followed by secondary antibody, goat anti-rabbit IgG-HRP, which was also
diluted 1:1000.  Lane assignments are as follows:  1=0 µg/L; 2=0.001 µg/L; 3,4,5,6=0.01
µg/L; 7=Kaleidoscope molecular weight standard (K); 8,9,10,11=0.1 µg/L; and
12,13,14,15=1.0 µg/L. Arrow at approximately 200 kDa indicates the expected molecular
weight of vitellogenin.  See methods for treatment regimens (Experiment 6).
[Representative individuals are shown, 5 individuals comprised each treatment group;
therefore, some may not be shown]
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Figure 30.  Vitellogenin concentration of sera from adult male Xenopus laevis after
immersion in ethinyl-estradiol at various doses. Treatment animals were immersed in
0, 0.0001, 0.001, 0.01, 0.1, or 1.0 µg/L ethinyl-estradiol dissolved in methanol (0.1%).
Bars represent mean (+/- standard error) serum vitellogenin concentrations of five frogs
per group calculated from the vitellogenin ELISA standard curve (Figure 5).  Different
letters above bars indicate significant differences between groups (Student-Newman-
Keuls, p<0.05). See methods for treatment regimens (Experiment 6).
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Figure 31.  Detection of hepatic vitellogenin mRNA using rt-PCR in male Xenopus
laevis after immersion in ethinyl-estradiol at various doses.  rt-PCR reactions were
performed using total hepatic RNA extracts (1 µg/reaction) from animals immersed in
0.0001, 0.001, 0.01, 0.1, or 1.0 µg/L ethinyl-estradiol dissolved in methanol (0.1%).
Vitellogenin-specific primers VTGC and VTGE were used.  RT-PCR reaction products
were separated on a 2% agarose gel and stained with ethidium bromide.  Lane
assignments are as follows:  1=0.0001 µg/L; 2=0.001 µg/L; 3=0.01 µg/L; 4=0.1 µg/L;
and 5=1.0 µg/L.  Arrow with 761 bp shows the expected product size for vitellogenin
mRNA using this primer pair.  See methods for treatment regimens (Experiment 6).
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Figure 32.  Protein concentration of sera from adult male Xenopus laevis after
immersion in various xenobiotic estrogens.  Negative controls © were untreated, while
vehicle controls (V) were immersed in methanol (0.1%).  Treatment animals were
immersed for 2 weeks in 200 µg/L of atrazine (A), nonylphenol (N), octylphenol (O), and
bisphenol-A (B) dissolved in methanol (0.1%).  Bars represent mean (+/- standard error)
protein concentration of five frogs per group calculated from a Coomassie assay.
Different letters above bars indicate significant differences between groups (Student-
Newman-Keuls, p<0.05). See methods for treatment regimens (Experiment 7).
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Figure 33.  Denaturing polyacrylamide gel electrophoresis (SDS-PAGE) of sera
from adult male Xenopus laevis after immersion in various xenobiotic estrogens.
Negative controls were untreated, while vehicle controls were immersed in methanol
(0.1%).  Treatment animals were immersed for 2 weeks in 200 µg/L atrazine , bisphenol-
A, octylphenol, or nonylphenol dissolved in methanol.  Lane assignments are as follows:
1,2,3,4=negative control (C); 5,6=vehicle control (V); 7=Sigma molecular weight
standard (S); 8=octylphenol (O); 9=nonylphenol (N); 10=bisphenol-A (B); and
11=atrazine (A). Arrow at approximately 200 kDa indicates the expected molecular
weight of vitellogenin. Sera were separated on a 4 to 15% polyacrylamide gradient gel
and stained with Coomassie blue. See methods for treatment regimens (Experiment 7).
[Representative individuals are shown, 5 individuals comprised each treatment group;
therefore, some may not be shown]
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Figure 34.  Effects of xenobiotic estrogens on serum vitellogenin induction in male
Xenopus laevis.  Indirect enzyme-linked immunosorbent assay was used to measure
vitellogenin levels in serum.  Primary antibody polyclonal #498 (rabbit anti-Xenopus
laevis vitellogenin) was used at a 1:1000 dilution followed by secondary antibody, goat
anti-rabbit IgG-HRP, which was also diluted 1:1000.  Negative controls (C) were
untreated, while vehicle controls (V) were immersed in methanol (0.1%).  Treatment
animals were immersed for 2 weeks in 200 µg/L atrazine (A), bisphenol-A (B),
octylphenol (O), or nonylphenol (N) dissolved in methanol (0.1%).  Bars represent mean
(+/- standard error) absorbance (450nm) of five frogs per group.  Different letters above
bars indicate significant differences between groups (Student-Newman-Keuls, p<0.05).
See methods for treatment regimens (Experiment 7).
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Figure 35.  Detection of hepatic vitellogenin mRNA using rt-PCR in male Xenopus
laevis after immersion in various xenobiotic estrogens.  rt-PCR reactions were
performed using total hepatic RNA extracts (1 µg/reaction) from a female (positive
control) injected (i.p.) with 0.25 cc ethinyl-estradiol weekly for 3 weeks, animals
immersed for 2 weeks in 200 µg/L atrazine, bisphenol-A, octylphenol, or nonylphenol
dissolved in methanol (0.1%), and untreated negative control males.  Vitellogenin-
specific primers F100 and R100 were used.  rt-PCR reaction products were separated on
a 2% agarose gel and stained with ethidium bromide.  Lane assignments are as follows:
Panel A: 1=positive control female (P); 2=100 bp DNA ladder (L); Panel B, C, D, E:
1=atrazine (A); 2=nonylphenol (N); 3=octylphenol (O); and 4=bisphenol-A.  Panel F: 1-
8= negative control males.  Arrow with 137 bp shows the expected product size for
vitellogenin mRNA using this primer pair.  See methods for treatment regimens
(Experiment 7).  [Each lane represents different individuals].
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Discussion
A large number of man-made chemicals have demonstrated estrogenic activity
(McLachlan, 1993).  These chemicals are abundant in the environment and are
considered to pose a health risk to wildlife and possibly humans (Colborn et al., 1993;
Danzo, 1998; Toppari et al., 1996; Turner and Sharpe, 1997).  The problems that could
arise from the presence of environmental estrogens has created a need for assays to test
compounds for estrogenicity.  Due to the structural differences between environmental
estrogens, assays must be based on biomarkers of estrogenicity (McLachlan, 1993).
Vitellogenin induction has proven to be an ideal biomarker in a variety of species,
especially fishes.  In this study I focused on an amphibian, Xenopus laevis as my model
organism.  I have developed assays to measure serum vitellogenin and hepatic
vitellogenin mRNA induction.  I demonstrated the effectiveness of these assays at
detecting vitellogenin induction after estrogen exposure by injection and immersion for
various times and doses.  I also tested the ability of various known xenobiotic estrogens
(atrazine, bisphenol-A, octylphenol, and nonylphenol) to stimulate vitellogenesis through
immersion.
Numerous bioassays, both in vitro and in vivo, have been developed to study
environmental estrogens, each having its own advantages and disadvantages.  Some
advantages of in vitro assays include low cost, rapid detection, and high throughput (Gray
et al., 1997).  The in vitro estrogenicity assays being used include the estrogen/androgen
receptor reporter gene assays (EDSTAC, 1998; Gray et al., 1997; Gray, 1998),
vitellogenin induction in trout hepatocytes (Pelissero et al., 1993), and growth of
estrogen-dependent breast cancer cells (Arnold et al., 1996; Soto et al., 1992,).  These
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assays are definitely valuable for initial screening; however, they have many
disadvantages.  In vitro assays are unable to account for physiological processes like
absorption, transport, storage, metabolism, and elimination, all of which influence
responsiveness to estrogenic compounds in a whole animal (Gray et al., 1997; Gray,
1998; Palmer and Selcer, 1996).  Some compounds are not estrogenic without metabolic
processing, while some compounds that are originally estrogenic may be metabolized to
an inactive form.  Therefore, in vitro assays can give false negative and false positive
results (Danzo, 1998).
Due to these limitations, in vivo assays might be more suitable for screening
estrogenic compounds.  In vivo assay advantages include accountability for absorption,
distribution, metabolism, and excretion of the estrogenic chemical, better utility in risk
assessment, applicability over a wide-range of species, and evaluation of the endocrine
system as a unit (Gray et al., 1997; Gray, 1998).  The disadvantages of in vivo assays are
high cost and they require more time.  The in vivo estrogenicity assays EPA is currently
proposing for endocrine disruptor screening include: the rodent uterotrophic assay, the
rodent pubertal male/female assay, the fish reproduction assay, and the rodent
reproduction assay (EDSTAC, 1998; Soto et al., 1992; Soto et al., 1995; Turner and
Sharpe, 1997).
Vitellogenin is useful as a biomarker for estrogenic compounds for many reasons
(Palmer and Selcer, 1996; Sumpter and Jobling, 1995; Toppari et al., 1996).  First,
vitellogenin induction is a physiological response to estrogen and the mechanism of its
production has been studied as a model for steroid action (Selcer and Palmer, 1995; Tata
and Smith, 1979).  Second, vitellogenin is produced by all nonmammalian vertebrates in
89
a dose-dependent manner and is normally female-specific (Ho et al, 1982).  Male
oviparous vertebrates will not have vitellogenin in their blood unless they are exposed to
estrogen.  Therefore, vitellogenin in the blood of male oviparous animals can serve as an
indicator (biomarker) of exposure to xenobiotic estrogens.  Lastly, vitellogenin is easily
quantified (Palmer and Selcer, 1996; Selcer and Palmer, 1995; Specker and Anderson,
1994).
Most in vivo assays for estrogenicity are based on vitellogenin induction in fish.
This is primarily due to the fact that they are fully aquatic and in contact with aquatic
environmental compounds at all life stages.  Additionally, there is an abundance of
sewage effluents that are contaminated with estrogens raising concerns about the effects
on numerous species of fish.  Many studies on fish species such as, zebrafish, rainbow
trout, lake trout, sheepshead minnows, fathead minnows, goldfish, flounder, plaice, and
sand goby, have confirmed that vitellogenin induction by such estrogens as ethinyl-
estradiol, octylphenol, nonylphenol, bisphenol-A, and atrazine is both time and dose
dependent (Bringolf et al., 2004; Craft et al., 2004; George et al., 2004; Karels et al.,
2003; Orn et al., 2003; Spano et al., 2004; Van den Belt et al., 2003; Verslycke et al.,
2002; Versonnen and Janssen, 2004; and Werner et al., 2003)
  In contrast, amphibians are under-represented in the field of endocrine disruption
and more information is needed on the effects of environmental contaminants on
amphibians.  Amphibian populations are declining worldwide due to causes yet unknown
(Phillips, 1999; Wake, 1991).  Endocrine disruptors have been suggested as one of the
causative agents of this decline; however, more research is needed.  Furthermore, some
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amphibian species are wonderful models for endocrine disruption because they are
aquatic, inexpensive, commercially available, and well studied.
My choice of Xenopus laevis was based largely on its utility as a laboratory
model.  It is a fully aquatic frog, which is beneficial for studies of aquatic contaminants
by immersion.  Additionally, it is a commonly used model in cellular and molecular
biology (Shapiro et al., 1989) and there is a considerable amount of information available
regarding the biology of this species, particularly its vitellogenic response to estrogens
(Palmer et al., 2001; Tata and Smith, 1979).
Experiment 1- Establishment of Controls
Our lab has previously evaluated vitellogenin induction after both injection and
immersion of adult male Xenopus laevis with diethylstilbesterol  (DES); (Selcer, et al.,
2001).  In the present study, ethinyl-estradiol was used.   This is perhaps a more relevant
estrogen, due to its presence in birth control pills.  The increasing number of women
using birth control pills places an increased amount of estrogens and their breakdown
products through sewage treatment plants and into the waterways.  This exposes wildlife
because these waters serve as breeding areas for adults and nurseries for offspring
(Sumpter and Jobling, 1995).
To produce vitellogenin for purification, adult females were injected with ethinyl-
estradiol and serum was collected.  Presence of vitellogenin was confirmed by SDS-
PAGE.  Western blotting further verified the presence of vitellogenin, because the
antibody (#498, Selcer et al., 2001) crossreacted with a protein band at about 200 kDa,
the known size of Xenopus laevis vitellogenin (Wahli et al., 1981).
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Next, a purified vitellogenin preparation was made for use in the standard curve.
Vitellogenin was purified using DEAE-MacroPrep beads.  Sera from negative control
males were also separated for comparison.  SDS-PAGE fractions revealed a 200 kDa
band in fractions taken from the high salt peak of females, representing vitellogenin.
Purified vitellogenin was obtained by pooling the high salt fractions from several DEAE
separations of female ethinyl-estradiol treated frog sera.  A standard curve was made
from the purified vitellogenin using direct ELISA.  The Xenopus vitellogenin ELISA was
sensitive and specific and could be used to quantify frog vitellogenin.
Previous experiments established that the rt-PCR assay could detect hepatic
vitellogenin mRNA from frogs that had been immersed in DES (Selcer et al., 2001).  A
similar result occurred with ethinyl-estradiol.  The rt-PCR procedure produced a cDNA
fragment of the expected size (761 bp) when hepatic mRNA from ethinyl-estradiol
injected females were tested using primers designed specifically for Xenopus laevis
vitellogenin.  In contrast, rt-PCR of hepatic mRNA from untreated males only resulted in
a product being amplified in one out of eight frogs.
Experiment 2 and 3 - Time Course Injection and Immersion
There was no consistent relationship between total serum protein concentration
and estrogen exposure by either injection or immersion.  For example, in the time course
immersion experiment vehicle controls did not differ from 4-week ethinyl-estradiol
treated males.  Therefore, total protein concentration is apparently not a good tool for
assessment of estrogen exposure.  It might be suspected that serum protein would
increase as vitellogenin increases.  However, estrogen exposure has actually been known
to lower certain proteins due to its ability to downregulate albumin and other proteins
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(Selcer and Palmer, 1995; Shapiro et al., 1989).  Downregulation of albumin is evident in
the SDS-PAGE gel comparing negative control males to 1, 2, and 4-week ethinyl-
estradiol injected males.  The band at approximately 70 kDa  (albumin) decreases over
time in ethinyl-estradiol treated frogs..
Both injection and immersion of ethinyl-estradiol caused plasma vitellogenin
levels to increase over time as evidenced by the SDS-PAGE gels and vitellogenin ELISA.
For injected animals, vitellogenin was evident by one week.  In contrast, vitellogenin was
not present until two weeks for immersed animals.  The amount of product amplified
from hepatic mRNA by rt-PCR did not differ between injection and immersion.
Furthermore, hepatic vitellogenin mRNA levels appear to be maximal at all times in both
treatments, probably due to the high doses used.
An injection of approximately 6,000 µg/kg ethinyl-estradiol administered in the
Xenopus time course injection study induced serum vitellogenin after one-week.  In
contrast, an injection of 1 µg/kg ethinyl-estradiol used by Brasfield et al. (2002) induced
plasma vitellogenin induction after just three days in the western fence lizard.  However,
the Brasfield et al. (2002) study used a competitive ELISA to detect plasma vitellogenin,
which is a more sensitive assay than direct ELISA used for Xenopus.  Plasma vitellogenin
remained elevated in western fence lizards over a period of 27 days, reaching maximum
induction on day 15 (Brasfield et al., 2002).  This is consistent with the Xenopus data in
which serum vitellogenin continued to increase over 30 days; however, serum
vitellogenin did not reach maximum induction until sometime between 15-30 days.  A
study by Verslycke et al. (2002) observed elevated plasma vitellogenin only after one-
week in juvenile rainbow trout injected with 10,000 µg/kg ethinyl-estradiol.  This is more
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consistent with the Xenopus results, probably due to the use of similar assays for
vitellogenin detection.
Xenopus immersed in 1 µg/L ethinyl-estradiol showed serum vitellogenin
induction after two weeks.  This is consistent with a study by Verslycke et al. (2002),
who observed plasma vitellogenin induction (via direct ELISA) two weeks after
immersion of juvenile rainbow trout in 1 µg/L ethinyl-estradiol.  Versonnen and Janssen
(2004) also detected plasma vitellogenin induction (via SDS-PAGE) two weeks after
immersion of adult zebrafish in 0.01 µg/L ethinyl-estradiol.
Experiment 4 – Primed Injection
When male Xenopus laevis are exposed to estradiol for the first time, 3-12 hours
pass before vitellogenin is induced (Ho, 1987).  Vitellogenin builds up in the blood over a
few days (primary response) and then declines to zero levels over a long period of time.
If estrogen is given a second time, a new round of vitellogenin synthesis occurs.  During
this secondary response, the lag period is shorter and the synthesis is more rapid and of a
higher quantity (Follett and Redshaw, 1974; Ho, 1987).    This is also called the “memory
effect” (Tata and Smith, 1979).  I hypothesized that estrogen-primed Xenopus laevis
males would be more sensitive to estrogens than unprimed animals and therefore
potentially more useful for biomarker analyses.
Protein concentrations were higher in all of the 30-day primed animals compared
to unprimed animals.  SDS-PAGE also revealed elevated vitellogenin levels in all primed
animals.  Therefore, 30 days was insufficient for vitellogenin to be removed in serum.
Similarly, all primed animals, including the 0 hour primed, showed maximal levels of
hepatic vitellogenin mRNA induction.  These data reveal that 30-day primed animals of
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this dose are not suitable for induction studies.  Lower doses or longer times are needed
to evaluate induction in primed animals.
The unprimed animals in this experiment provide information on the time course
of mRNA induction.  Unprimed animals showed detectable vitellogenin mRNA at four
hours and this increased at eight hours and twelve hours.  This is consistent with previous
reports (Ho, 1987; Tata and Smith, 1979).
Experiment 5 and 6 – Dose Response Injection and Immersion
Total protein concentrations were not consistently different between doses for
either the dose-response injection or immersion studies.  However, in both dose-response
injection and immersion, SDS-PAGE gels showed visible dose-dependent differences in
serum vitellogenin amounts.   The minimum response dose, evidenced on SDS-PAGE
gels, in the injection study was 1000 µg/kg ethinyl-estradiol, while in the immersion
study it was 0.1 µg/L ethinyl-estradiol.  Additionally, the vitellogenin ELISA was able to
quantify serum vitellogenin after a minimum dose of 1000 µg/kg ethinyl-estradiol in the
injection study and a minimum dose of 0.01 µg/L ethinyl-estradiol in the immersion
study.  This reveals the heightened sensitivity of the vitellogenin ELISA compared to
SDS-PAGE.
Our results on injection of ethinyl-estradiol are not only comparable to those
results represented in the literature, but are also based on environmentally relevant doses.
For example, Brasfield et al. (2002) observed induction of plasma vitellogenin in male
western fence lizards in a dose-dependent manner to ethinyl-estradiol concentrations
ranging from 0.3-10,000 µg/kg with a minimum response dose of 0.3 µg/kg ethinyl-
estradiol.  This minimum response dose is much lower than the Xenopus minimum
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response dose of 1000 µg/kg ethinyl-estradiol; however, this may be due to the different
assays used for detection of vitellogenin.  Brasfield et al. (2002) used a competitive
ELISA to detect and quantify plasma vitellogenin, whereas the Xenopus assay used was a
direct ELISA, which is less sensitive.
Most studies use immersion as opposed to injection, in assessing vitellogenin
induction.  Immersion is more environmentally relevant, due to the fact that this is the
major route of exposure in wildlife populations.  For example, Van den Belt et al. (2003)
immersed both male zebrafish and juvenile rainbow trout in ethinyl-estradiol
concentrations ranging from 0.005-0.025 µg/L.  Both species produced plasma
vitellogenin in a dose-dependent manner with a minimum response dose of 0.005 µg/L
ethinyl-estradiol for each.  This dose is more than ten-fold less than the minimum
response dose in Xenopus (0.01 µg/L).  This difference could be attributable to the
duration of the studies.  Fourteen days of exposure was used to measure Xenopus serum
vitellogenin induction; whereas, 21 days was used to measure induction in the Van den
Belt et al. (2003) study.  Also, even though both studies employed a direct ELISA to
quantify serum vitellogenin, the standard curve constructed in the Van den Belt study was
based on vitellogenin enriched plasma quantified via densitometry, as opposed to purified
vitellogenin, which was used in the Xenopus study.
Another dose-response immersion study using ethinyl-estradiol (Purdom et al.,
1994) was able to detect dose-dependent plasma vitellogenin induction in carp at a
minimum response dose of 0.01 µg/L ethinyl-estradiol after ten days of exposure.
Similarly, Versonnen and Janssen (2004) using ethinyl-estradiol concentrations ranging
from 0.001-0.1 µg/L were able to detect dose-dependent plasma vitellogein induction in
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adult zebrafish at a minimum response dose of 0.01 µg/L ethinyl-estradiol after 14 days
of exposure.  Both of these studies are consistent with the Xenopus data.
Conversely, Werner et al. (2003) using ethinyl-estradiol concentrations ranging
from 0.004-0.4 µg/L were able to detect dose-dependent plasma vitellogenin induction in
lake trout at a minimum response dose of 0.004 µg/L ethinyl-estradiol.  This a lower dose
than the minimum response dose in Xenopus, zebrafish, and carp. This difference could
be due to the longer duration of the Werner et al. (2003) study (21 days compared to 14
days).  Ethinyl-estradiol concentrations ranging from 0.00013-0.026 µg/L also induced
dose-dependent plasma vitellogenin production with a minimum response dose of 0.001
µg/L ethinyl-estradiol in immature female rainbow trout (Thomas-Jones et al., 2003).
This dose is ten-fold less than the minimum response dose in Xenopus for the same time
period.  Perhaps because they were females, even though they were immature, they were
producing plasma vitellogenin naturally in addition to that induced by ethinyl-estradiol
exposure.
Lastly, Folmar et al. (2000) and Bowman et al. (2000) both observed dose-
dependent plasma vitellogenin induction in male sheepshead minnows in response to
ethinyl-estradiol with a minimum response dose of 0.1 µg/L ethinyl-estradiol.  This is
higher than the minimum dose detected for Xenopus, possibly indicating lowered
sensitivity in sheepshead minnows.
Hepatic vitellogenin mRNA also responded in a dose-dependent manner to
ethinyl-estradiol.  However, vitellogenin mRNA was detected at much lower levels than
was serum vitellogenin.  The minimum response dose in the dose-response injection
study was 0.1 µg/kg ethinyl-estradiol.  The minimum response dose in the dose-response
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immersion study was 0.0001 µg/L ethinyl-estradiol.  Thomas-Jones et al. (2003) was also
able to detect dose-dependent hepatic vitellogenin mRNA in immature female rainbow
trout at a minimum response dose of 0.001 µg/L ethinyl-estradiol.  Additionally, Folmar
et al. (2000) and Bowman et al. (2000) were able to detect hepatic vitellogenin mRNA,
which was dose responsive, in sheepshead minnows at a minimum response dose of 0.1
µg/L ethinyl-estradiol.  Xenopus mRNA induction was detectable at a lower dose than the
aforementioned studies.  Maybe amphibians are more sensitive to estrogen at lower levels
or maybe the Xenopus hepatic mRNA assay is more sensitive.  It is possible that the other
studies did not include enough cycles in their rt-PCR programs to allow for amplification
of miniscule amounts of cDNA.   Collectively, these data illustrate the sensitive nature of
rt-PCR and its efficiency to detect induction of vitellogenin mRNA at very small doses of
estrogen.
Experiment 7 – Xenobiotic Immersion
Total protein concentrations showed some differences between the xenobiotic
treatment groups, but no group was different from controls, again demonstrating that total
protein is not a useful indicator of exposure.
Hepatic vitellogenin mRNA was induced in some xenobiotic exposed frogs.
Octylphenol appeared to be the most estrogenic.  Some nonylphenol-treated individuals
also responded, but to a lesser degree.  There is considerable variation in the literature as
to the relative estrogenic potencies of nonylphenol and octylphenol.  Some studies report
octylphenol to be a more potent estrogen (Andersen et al., 1999; White et al., 1994),
while others have shown nonylphenol to be more estrogenic (Coldham et al., 1997).
Andersen et al. (1999) suggested that the variation between studies might be attributable
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to differences in the grade and isomeric composition of these two compounds from
different commercial sources.
Bisphenol-A also generated a substantial amount of product, thus proving itself to
be quite estrogenic.  This finding is consistent with other studies that have shown
bisphenol-A to be among the most potent of the estrogenic pollutants.  For example,
Andersen et al. (1999) reported that bisphenol-A produced higher estrogenic response
among more than a dozen environmental chemicals tested in each of the various in vitro
estrogenicity assays they used.
Some Xenopus also responded to atrazine, but to a lesser degree than bisphenol-A,
octylphenol, and nonylphenol.  Only preliminary studies have been done assessing
atrazines impact on hepatic vitellogenin mRNA induction in wildlife.  Most studies,
including Hayes et al. (2002a,b), have focused on developmental deformities and
reproductive abnormalities.
Despite the induction of hepatic vitellogenin mRNA indicated by the rt-PCR
assay after immersion in the xenobiotics, there was no indication of serum vitellogenin in
any of the frogs, indicated by SDS-PAGE and ELISA.  Andersen et al. (1999) reported
that bisphenol-A, but not nonylphenol, induced serum vitellogenin after nine days in trout
that received a single injection of 50 mg/kg.  However, nonylpheno has been shown to
elevate serum vitellogenin in other studies (Lech et al., 1996; Christiansen et al., 1998).
The absence of serum vitellogenin in Xenopus immersed in xenobiotics could be due to
insufficient time of immersion for serum vitellogenin to accumulate to detectable levels.
Also, it may be that the xenobiotic-induced elevation of hepatic vitellogenin mRNA is
99
below the threshold necessary to result in sufficient protein production for accumulation
of serum vitellogenin.
The choice of 200 µg/L for exposure to the xenobiotics is both environmentally
relevant and similar to those doses reported in other studies.  In concordance with
Xenopus results, other studies were also unable to induce serum vitellogenin induction
with some xenobiotic estrogens.  For instance, Spano et al. (2004) was unable to detect
plasma vitellogenin induction in adult goldfish after immersion in 100 or 1000 µg/L
atrazine.  Similarly, Bringolf et al. (2004) were also unable to induce plasma vitellogenin
induction in fathead minnows after immersion in 5 or 50 µg/L atrazine.  Lastly, Van den
Belt et al. (2003) was unable to induce significant plasma vitellogenin induction in male
zebrafish after immersion in various doses of octylphenol (12.5, 25, 50, and 100 µg/L).
In contrast, other studies have reported induction of plasma vitellogenin by some
xenobiotics.  Van den Belt et al. (2003) were able to induce plasma vitellogenin induction
in juvenile rainbow trout at a minimum response dose of 30 µg/L octylphenol.  Plasma
vitellogenin was also induced in juvenile rainbow trout and male zebrafish by immersion
in nonlyphenol.  Both species responded at 20 µg/L nonylphenol; however, zebrafish was
three-times less sensitive than rainbow trout to nonlyphenol.  Increased mortality was
observed at 500 µg/L nonylphenol in rainbow trout, while male zebrafish were
unaffected.  Two-hundred µg/L bisphenol-A also induced plasma vitellogenin production
in both species.  Finally, Karels et al. (2003) successful induced serum vitellogenin
induction in sheepshead minnows after immersion in octylphenol at a minimum response
dose of 11.5 µg/L.
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The induction in the aforementioned studies could be due to longer exposure
times (21-24 days, as opposed to 14 days in the Xenopus study).  Also as previously
mentioned the grade of the chemical sometimes affects its ability to elicit a response.
Finally, species sensitivity is another factor to consider.  Fish may be more sensitive than
amphibians to xenobiotic estrogens, due to their physiology.
Negative and Vehicle Control Issue
In early rt-PCR experiments, some negative and vehicle control animals showed
vitellogenin PCR products, although all negative and vehicle controls had undetectable
serum vitellogenin.  This could have been due to either cross-contamination with PCR
products from estrogen-treated animals or to actual vitellogenin mRNA synthesis in these
untreated frogs.  To test this, freshly shipped Xenopus laevis were immediately sacrificed
upon arrival.  They did not come into contact with any estrogen-treated individuals or
tanks that housed estrogen-treated individuals.  Also, they were not fed NASCO frog
brittle, which was used to feed the frogs in other experiments.  The mRNA from these
untreated frogs was extracted at a different time, than mRNA from any treated
individuals to avoid cross-contamination.  Additionally, different instruments were used
from previous experiments.   Hepatic vitellogenin rt-PCR only revealed amplified
product in one out of eight individuals.  This leads to the conclusion that some males
possess vitellogenin mRNA.  This could possibly be due to what they were fed prior to
shipment.  During previous studies frogs were fed NASCO frog brittle, which upon
examination of the ingredients was found to contain soy extracts, which are
phytoestrogens. Suppliers may also be feeding frogs food containing similar ingredients.
It is possible that the food was able to supply enough estrogen to the negatives and
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vehicles to stimulate vitellogenin mRNA induction; however, not enough to induce serum
vitellogenin.
Vitellogenin ELISA
A broad asymptotic standard curve was generated using numerous concentrations
of purified vitellogenin and purified antibody #498 (Selcer et al., 2001).  The curve
allowed for sensitive quantification of serum vitellogenin in all of the studies.  A standard
curve based on competitive ELISA has been used in some other studies, and found to be
more sensitive.  Serum does not have to be diluted as much in competitive ELISAs;
whereas, serum has to be diluted 1:9000 in direct ELISAs, resulting in an automatic
decrease in sensitivity.  Competitive ELISAs were attempted in this study according to
Specker and Anderson (1994); however, a standard curve was unable to be generated.
Countless revisions were made to the protocol and many attempts were made, but to no
avail.  Future work on this project could focus on developing a working competitive
ELISA, possibly using a new antibody.
rt-PCR
The hepatic mRNA rt-PCR assay is a highly sensitive and rapid assay for
determining in vivo exposure to both potent and weak environmental estrogens, capable
of detecting vitellogenin mRNA at much lower doses and for shorter periods of exposure
time than serum can be detected.  mRNA appears substantially earlier than serum;
therefore, detection of mRNA via rt-PCR is a more rapid way to assess acute estrogen
exposure. George et al. (2004) and Craft et al. (2004) both studied vitellogenin mRNA
induction after exposure to estrogen in various fish species (flounder, plaice, and sand
goby).  They both concluded, similar to Xenopus, that vitellogenin mRNA does in fact
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increase earlier and was more sensitive to lower exposure doses than serum vitellogenin.
The ability to detect a response quickly and the higher sensitivity increase the utility of
the assay for screening potential environmental estrogens.
However, with the rt-PCR assay as we used it, only a qualitative assessment can
be made in regards to quantity of product amplified.  Real-time PCR would be a better
alternative for quantifying vitellogenin mRNA.  Real-time PCR was attempted in this
study and progress was made.  Vitellogenin amplification was possible, but the
background (due to primer dimers) interfered too much for accurate quantification.
Future work on this project could focus on designing better primer pairs, eliminating
primer dimers.  Real-time PCR would be the most sensitive assay for measuring estrogen
exposure,
Significance
In this study assays were developed to measure vitellogenin induction by
estrogenic compounds in an amphibian model system.  This included development and
validation of a vitellogenin ELISA for measurement of this protein in Xenopus laevis
serum and a specific vitellogenin rt-PCR assay for determination of vitellogenin hepatic
mRNA induction.  These assays should be especially useful for studies on endocrine
disruption.  First, suspected estrogenic compounds can be screened with these assays.
Adult male frogs can be injected or immersed in the compounds and vitellogenin
production can be measured.  Second, waters from locations suspected to be polluted
with estrogenic agents (i.e. downstream of sewage effluents) could be tested by placing
adult male frogs into water samples brought back to the lab and measuring vitellogenin
production.  Data from these studies on Xenopus can also be compared with data
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collected for other species (mostly fish) to determine whether or not amphibians respond
similarly.
It should be reiterated that amphibians are under represented in toxicological
studies.  The only amphibian toxicity model widely used is the Xenopus FETAX assay.
The new Xenopus vitellogenin assays provide a new tool for assessment of toxic agents in
amphibians.  Xenopus vitellogenin induction could be used as a universal screen for
endocrine disruptors along with the already proposed EDSTAC (EPA) in vivo assays (i.e.
the rodent uterotrophic assay, the rodent pubertal male/female assay, the fish
reproduction assay, and the rodent reproduction assay).
104
Perspectives
Data continue to mount regarding the impact of endocrine disruptors on wildlife.
However, the biggest controversy is how much they are affecting humans. Even though
the investigation into human health effects has just begun, some startling effects have
already been suggested as attributable to endocrine disruptors.  These include immune
system changes, neurological and motor delays, and learning problems in children
(Colborn et al 1993).
Lou Guillette made this startling statement at a Congressional hearing regarding
the finding of reduced sperm counts, “Every man sitting in this room today is half the
man his grandfather was.  And the question is, “Are our children going to be half the men
we are”?  This scientific evidence raises some important questions about the extent to
which endocrine disrupting chemicals are altering children’s ability to learn, function,
resist disease, and reproduce. If the outcomes are as big as some speculate, delaying
control and elimination practices could cause irreversible damage to the next generation
(Colborn et al. 1993).
The authors of Our Stolen Future (1996) stated, “that if such substances are
causing wide-scale disruption of the hormones that enable us to grow and reproduce, we
may be witnessing an evolutionary tragedy in the making.”  Additional research is needed
to support such a bold statement regarding endocrine disruptors and human health;
however, the verdict is already out on wildlife populations, which are currently
experiencing problems due to endocrine disruption.  Therefore, the focus of the research
needs to shift to species of special concern including frogs and marine mammals who are
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suffering the most, and to human groups at special risk including, children (embryos and
fetuses).
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